Histone deacetylase 6 structure and molecular basis of catalysis and inhibition
Open accessAbstract
Histone deacetylase 6 (HDAC6) is a critical target for drug design because of its role in oncogenic transformation and cancer metastasis, and is unique among all histone deacetylases in that it contains tandem catalytic domains designated CD1 and CD2. We now report the crystal structures of CD2 from Homo sapiens HDAC6 and of CD1 and CD2 from Danio rerio HDAC6. We correlated these structures with activity measurements using 13 different substrates. The catalytic activity of CD2 from both species exhibited broad substrate specificity, whereas that of CD1 was highly specific for substrates bearing C-terminal acetyllysine residues. Crystal structures of substrate complexes yielded unprecedented snapshots of the catalytic mechanism. Additionally, crystal structures of complexes with eight different inhibitors, including belinostat and panobinostat (currently used in cancer chemotherapy), the macrocyclic tetrapeptide HC toxin, and the HDAC6-specific inhibitor N-hydroxy-4-(2-((2-hydroxyethyl)(phenyl)amino)-2-oxoethyl)benzamide, revealed surprising new insight regarding changes in Zn(2+) coordination and isozyme-specific inhibition.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
7 of 15 cited sources checked · 5 supported · 1 flagged · accuracy not yet measured
- Premisecitation
In HDAC8, the conserved D101 accepts hydrogen bonds from the two backbone amide groups that flank the scissile acetyllysine.
“In HDAC8, highly conserved D101 accepts hydrogen bonds from the two backbone amide groups flanking the scissile acetyllysine residue.37,38”
Quote in the paperSubstantial claim2 of 2 sources checked- cites [37] Vannini, A. et al. Substrate binding to histone deacetylases as shown by the crystal structure of the HDAC8-substrate complex. EMBO Rep. 8, 879–884 (2007). source
- cites [38] Dowling, D.P., Gantt, S.L., Gattis, S.G., Fierke, C.A. & Christianson, D.W. Structural studies of human histone deacetylase 8 and its site-specific variants complexed with substrate and inhibitors. Biochemistry 47, 13554–13563 (2008). source
The Results and Discussion state that strictly conserved D101 accepts hydrogen bonds from two substrate backbone NH groups. They identify those groups as belonging to the acetyllysine residue itself and the adjacent n+1 residue, rather than two residues flanking the acetyllysine. (LLM, conf=0.84)
Experimental — accuracy not yet measured
- Premisecitation
In HDAC8, the second histidine of the tandem pair acts as a single general base-general acid.
“this contrasts with HDAC8, in which the second histidine of the tandem pair serves as a single general base-general acid.33”
Quote in the paperNot a substantial claim1 of 1 sources checked- cites [33] Gantt, S.M. et al. General base-general acid catalysis in human histone deacetylase 8. Biochemistry 55, 820–832 (2016). source
- Findingreasoning
K330L zCD1 has more relaxed substrate specificity than wild-type zCD1.
“Consistent with this hypothesis, K330L zCD1 exhibited more relaxed substrate specificity in comparison with wild-type zCD1 (Supplementary Fig. 2).”
- Also stated in: § Basis of CD1 specificity for X-K(Ac)-CO2− substrates · plain
“K330L zCD1 exhibited more relaxed substrate specificity in comparison with wild-type zCD1”
Quote in the paperSubstantial claim0 of 1 sources checked- cites Supplementary Fig. 2
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Also stated in: § Basis of CD1 specificity for X-K(Ac)-CO2− substrates · plain
- Findingown data
The 1.80 Å structure of substrate 8 bound to H574A zCD2 provides a snapshot of the tetrahedral intermediate.
“the next snapshot of catalysis – the tetrahedral intermediate – was provided by the 1.80 Å-resolution structure of the complex between substrate 8 (derived from histone H4) and H574A zCD2.”
Quote in the paperSubstantial claim - Findingown data
In the resting zCD2 structure, the catalytic Zn2+ ion sits at the bottom of a roughly 10 Å deep tunnel and is coordinated by D612, H614, D705, and a water molecule in distorted tetrahedral geometry.
“the crystal structure of the resting enzyme showed that the catalytic Zn2+ ion resides at the base of a ~10 Å deep tunnel, liganded by D612, H614, D705, and a water molecule with distorted tetrahedral coordination geometry.”
Quote in the paperSubstantial claim
- Findingown data
H574A zCD2 has reduced activity because it lacks the catalytically required general acid.
“This mutant exhibited compromised activity due to the loss of the catalytically obligatory general acid.”
Quote in the paperSubstantial claim - Findingown data
The active site contours of zCD2 and hCD2 are highly similar.
“their active site contours were highly similar.”
Quote in the paperSubstantial claim - Findingown data
Y745F zCD2 has reduced activity because Y745 can no longer activate the substrate.
“we prepared Y745F zCD2, which exhibited compromised activity due to the loss of substrate activation by Y745.”
Quote in the paperSubstantial claim - Findingown data
Catalytic efficiency falls only 3-4-fold for the least favored substrates 11 and 13 relative to the optimal substrate 12.
“the catalytic efficiency was reduced by only 3–4-fold when the least favored substrates 11 and 13 were compared to the optimal substrate 12”
Quote in the paperSubstantial claim - Findingown data
CD2 from human and zebrafish HDAC6 has broad substrate specificity.
“The catalytic activity of CD2 from both species exhibits broad substrate specificity”
Quote in the paperSubstantial claim - Findingown data
Mutating hCD2, but not hCD1, reduces catalytic efficiency by more than 400-fold.
“mutation of hCD2, but not hCD1, leads to more than 400-fold decreased catalytic efficiency (kcat/KM).”
Quote in the paperSubstantial claim - Findingown data
zCD2 has about tenfold higher catalytic activity than hCD2.
“zCD2 exhibited ~10-fold enhanced catalytic activity compared with hCD2”
Quote in the paperSubstantial claim - Findingown data
zCD1 prefers substrates 9 and 10, which have C-terminal acetyllysine residues.
“zCD1 similarly preferred substrates 9 and 10, which bear C-terminal acetyllysine residues.”
Quote in the paperNot a substantial claim - Findingown data
CD1 is highly selective for substrates that have a C-terminal acetyllysine residue.
“whereas that of CD1 is highly specific for substrates bearing C-terminal acetyllysine residues”
Quote in the paperSubstantial claim - Findingown data
Structures of substrate complexes provide snapshots of the catalytic mechanism.
“Crystal structures of substrate complexes yield unprecedented snapshots of the catalytic mechanism.”
Quote in the paperSubstantial claim - Findingown data
Structures of complexes with eight inhibitors reveal new information about changes in Zn2+ coordination and about isozyme-specific inhibition.
“crystal structures of complexes with 8 different inhibitors, including Belinostat and Panobinostat (currently used in cancer chemotherapy), the macrocyclic tetrapeptide HC toxin, and the HDAC6-specific inhibitor N-hydroxy-4-(2-[(2-hydroxyethyl)(phenyl)amino]-2-oxoethyl)benzamide, reveal surprising new insight regarding changes in Zn2+ coordination and isozyme-specific inhibition.”
Quote in the paperSubstantial claim - Findingown data
The water molecule bound to Zn2+ also hydrogen bonds with H573 and H574.
“The Zn2+-bound water molecule also formed hydrogen bonds with H573 and H574.”
Quote in the paperNot a substantial claim - Findingown data
Crystal structures were determined for zebrafish CD2 in complex with SAHA, Belinostat, Panobinostat, Oxamflatin, and HPOB.
“In addition to the previously described structures of hCD2, zCD1, and zCD2 complexed with TSA, we also determined crystal structures of zCD2 complexed with clinically-approved broad-specificity hydroxamate inhibitors SAHA, Belinostat, and Panobinostat; Oxamflatin; and the HDAC6-selective inhibitor N-hydroxy-4-(2-[(2-hydroxyethyl)(phenyl)amino]-2-oxoethyl)benzamide (HPOB) (Supplementary Fig. 10).43”
Quote in the paperSubstantial claim - Findingown data
TSA binds in notably different orientations in the zCD1 and zCD2 active sites.
“the inhibitor TSA adopted a notably different binding orientation in each active site”
Quote in the paperSubstantial claim - Findingown data
The unactivated ketone of the α,β-epoxyketone moiety becomes hydrated in the zCD2 active site.
“It was surprising that the unactivated ketone of the α,β-epoxyketone moiety underwent hydration in the zCD2 active site.”
Quote in the paperSubstantial claim - Findingown data
The macrocyclic peptide backbone of HC toxin makes interactions similar to those of the substrate peptide backbone.
“interactions of the macrocyclic peptide backbone of HC toxin were similar to interactions with the substrate peptide backbone”
Quote in the paperSubstantial claim - Findingown data
The hydroxamate groups of all broad-specificity inhibitors tend toward bidentate Zn2+ coordination, displacing the Zn2+-bound water molecule of the resting enzyme.
“Additionally, the hydroxamate groups of all broad-specificity inhibitors tended toward bidentate Zn2+ coordination (Fig. 5b and Supplementary Table 5), displacing the Zn2+-bound water molecule of the resting enzyme, with the hydroxamate OH and C=O groups additionally interacting with H573 and Y745, respectively.”
Quote in the paperSubstantial claim - Findingown data
The Zn2+ ions, catalytic residues, and L1 and L2 loops flanking the active sites align well between zCD1 and zCD2.
“The Zn2+ ions, catalytic residues, and L1 and L2 loops flanking the active sites aligned well.”
Quote in the paperNot a substantial claim - Findingown data
HPOB has a Ki of 1.0 nM against HDAC6.
“In contrast, the hydroxamate group of the HDAC6-selective inhibitor HPOB (Ki = 1.0 nM) coordinated to Zn2+ only through its OH group, and it did not displace the Zn2+-bound water molecule; the Zn2+ ion is pentacoordinate with square pyramidal geometry (Fig. 5c).”
Quote in the paperSubstantial claim - Findingown data
The hydroxamate C=O group of HPOB hydrogen bonds with the Zn2+-bound water molecule.
“The hydroxamate C=O group hydrogen bonded with the Zn2+-bound water molecule.”
Quote in the paperSubstantial claim - Findingown data
Peptide substrate binding to HDAC6 zCD2 differs significantly from binding to the class I enzyme HDAC8.
“Binding interactions of peptide substrates to HDAC6 zCD2 and the well-studied class I enzyme HDAC8 differ significantly.”
Quote in the paperSubstantial claim - Findingown data
In zCD1, W78 changes conformation toward the bound inhibitor because of a steric interaction with E138 on a nearby helix.
“Another difference evident in the active site of zCD1 was the conformational change of W78 toward the bound inhibitor, resulting from a steric interaction with E138 on a nearby helix.”
Quote in the paperSubstantial claim - Findingown data
The cap groups of broad-specificity inhibitors cluster around a hot spot on the L1 loop (D460-P484) and contact H463 and P464.
“First, the “cap” moieties of broad-specificity inhibitors clustered around a “hot spot” on the L1 loop (D460-P484), making contacts with H463 and P464 (Fig. 5a).”
Quote in the paperSubstantial claim - Findingown data
In the HPOB complex, the Zn2+ ion is pentacoordinate with square pyramidal geometry.
“In contrast, the hydroxamate group of the HDAC6-selective inhibitor HPOB (Ki = 1.0 nM) coordinated to Zn2+ only through its OH group, and it did not displace the Zn2+-bound water molecule; the Zn2+ ion is pentacoordinate with square pyramidal geometry (Fig. 5c).”
Quote in the paperSubstantial claim - Findingown data
The zCD1-TSA complex resembles the zCD2-TSA complex, with an r.m.s. deviation of 0.58 Å over 311 Cα atoms.
“The structure of this complex was similar to that of the zCD2-TSA complex, with an r.m.s. deviation of 0.58 Å for 311 Cα atoms.”
Quote in the paperNot a substantial claim - Findingreasoning
The thiol side chain of C584 is oriented for nucleophilic attack at the less hindered epoxide carbon.
“The thiol side chain of this residue is oriented for nucleophilic attack at the less hindered epoxide carbon.”
Quote in the paperSubstantial claim - Findingown data
The L1 and L2 loops flanking the active site are relatively rigid, as revealed in the 12 zCD2 structures reported herein.
“Additionally, the L1 and L2 loops flanking the active site are relatively rigid, as revealed in the 12 zCD2 structures reported herein, making HDAC6 an ideal receptor for in silico docking experiments.”
Quote in the paperSubstantial claim - Findingreasoning
The CD1 domains of human and zebrafish HDAC6 exhibit stringent specificity for acetyllysine substrates bearing a free α-carboxylate group.
“In contrast, the CD1 domains of human and zebrafish HDAC6 exhibit stringent specificity for acetyllysine substrates bearing a free α-carboxylate group, likely due to hydrogen bond interactions with gatekeeper residues K353 and Y225 (hCD1 numbering) as well as a more constricted active site contour.”
Quote in the paperSubstantial claim - Findingreasoning
In binding as the gem-diol, the α,β-epoxyketone moiety of HC toxin binds as a tetrahedral transition state analogue rather than a substrate analogue with an intact ketone carbonyl.
“Moreover, in binding as the gem-diol, the α,β-epoxyketone moiety of HC toxin binds as a tetrahedral transition state analogue rather than a substrate analogue with an intact ketone carbonyl.”
Quote in the paperSubstantial claim - Findingnone given
HDAC6-peptide recognition is similar for substrates and the macrocyclic peptide inhibitor HC toxin.
“Significantly, HDAC6-peptide recognition is similar for substrates as well as the macrocyclic peptide inhibitor HC toxin.”
Quote in the paperSubstantial claim - Interpretationreasoning
The zebrafish enzyme is a valid surrogate for the human enzyme.
“Therefore, the zebrafish enzyme was judged to be a valid surrogate for the human enzyme.”
Quote in the paperSubstantial claim - Interpretationreasoning
The hCD2 domain, even when inactivated by Y782F, likely stabilizes the hCD1 domain in hCD12 so that hCD1 can reach optimal catalytic activity.
“Presumably, the hCD2 domain, even though inactivated by the Y782F substitution, structurally stabilized the hCD1 domain in hCD12 for optimal catalytic activity.”
Quote in the paperSubstantial claim - Interpretationreasoning
Both Zn2+ and Y745 are required to activate the substrate carbonyl for nucleophilic attack.
“both Zn2+ and Y745 must be necessary to activate the substrate carbonyl for nucleophilic attack.”
Quote in the paperSubstantial claim - Premisecitation
HDAC6 is the only histone deacetylase that has two catalytic domains, CD1 and CD2.
“HDAC6 is unique in that it contains tandem catalytic domains CD1 and CD2,19”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [19] Grozinger, C.M., Hassig, C.A. & Schreiber, S.L. Three proteins define a class of human histone deacetylases related to yeast Hda1p. Proc. Natl. Acad. Sci. USA 96, 4868–4873 (1999). source
- Interpretationown data
A coordination site on Zn2+ that appears vacant could bind a ligand that also contacts Y745.
“A seemingly vacant coordination site on Zn2+ would allow for the binding of a ligand that could also interact with Y745”
Quote in the paperSubstantial claim - Interpretationreasoning
The active site nucleophile in HDAC6 must be positioned slightly differently from that in class I HDACs.
“Thus, there must be slight differences in the positioning of an active site nucleophile in the HDAC6 active site compared with class I HDACs.”
Quote in the paperSubstantial claim - Interpretationown data
The serine residue that is strictly conserved in both catalytic domains of HDAC6 orthologues is crucial for positioning the scissile acetyllysine in the enzyme-substrate complex.
“this serine residue, which is strictly conserved in both catalytic domains of HDAC6 orthologues across all species (Supplementary Fig. 7), is crucial for positioning the scissile acetyllysine residue in the enzyme-substrate complex.”
Quote in the paperSubstantial claim - Interpretationown data
Y225 in hCD1 is another gatekeeper that gives specificity for C-terminal acetyllysine substrates.
“Therefore, Y225 in hCD1 is another “gatekeeper” that confers specificity toward C-terminal acetyllysine substrates.”
Quote in the paperSubstantial claim - Interpretationown data
The nearly symmetric bidentate carboxylate-Zn2+ coordination is helped by negative charge delocalized over both carboxylate oxygens.
“Nearly symmetric bidentate carboxylate-Zn2+ coordination was facilitated by the negative charge delocalized over both carboxylate oxygen atoms.”
Quote in the paperNot a substantial claim - Interpretationreasoning
Inhibitor binding to class I HDAC active sites presumably allows for a closer contact between the nucleophilic thiol and the electrophilic epoxide to enable covalent bond formation.
“Presumably, inhibitor binding to class I HDAC active sites allows for a closer contact between the nucleophilic thiol and the electrophilic epoxide to enable covalent bond formation.”
Quote in the paperSubstantial claim- Rests on an assumption: The active site geometry of class I HDACs is sufficiently similar to zCD2 that the nucleophile and inhibitor binding conclusions transfer.
- Interpretationreasoning
The stringent specificity of HDAC6 CD1 for substrates with a free α-carboxylate is likely due to hydrogen bond interactions with gatekeeper residues K353 and Y225 and a more constricted active site contour.
“In contrast, the CD1 domains of human and zebrafish HDAC6 exhibit stringent specificity for acetyllysine substrates bearing a free α-carboxylate group, likely due to hydrogen bond interactions with gatekeeper residues K353 and Y225 (hCD1 numbering) as well as a more constricted active site contour.”
Quote in the paperSubstantial claim - Interpretationreasoning
Drug discovery programs using in vitro assays of HDAC6 with traditional fluorogenic substrates will yield hits exclusively targeting hCD2 and miss the highly specific activity of hCD1.
“Regardless, in view of the highly specialized binding activity and catalytic function of hCD1, we suggest that drug discovery programs employing in vitro assays of HDAC6 using traditional fluorogenic substrates will yield “hits” exclusively targeting hCD2 that miss the highly specific activity of hCD1.”
Quote in the paperSubstantial claim - Interpretationreasoning
The binding mode of HC toxin likely represents the binding mode of other Aoe-containing cyclic tetrapeptides such as trapoxin A to all other HDAC isozymes, whether or not these inhibitors bind reversibly or irreversibly.
“This likely represents the binding mode of other Aoe-containing cyclic tetrapeptides such as trapoxin A to all other HDAC isozymes, whether or not these inhibitors bind reversibly or irreversibly.”
Quote in the paperSubstantial claim - Interpretationreasoning
The short, bulky linker of HPOB sterically precludes a closer approach of its hydroxamate group to Zn2+.
“The short, bulky linker of HPOB sterically precluded a closer approach of the hydroxamate group to Zn2+, which may also have prevented the “cap” moiety of HPOB from interacting with the L1 loop, an interaction that appears to be more important for binding to HDACs 1-3 than to HDAC6.”
Quote in the paperSubstantial claim - Interpretationreasoning
Based on the geometry observed in the zCD2-HC toxin complex, the likely active site nucleophile is the strictly conserved residue C584.
“Based on the geometry observed in the zCD2-HC toxin complex, the likely active site nucleophile is the strictly conserved residue C584.”
Quote in the paperSubstantial claim - Interpretationreasoning
Any carbonyl (peptide, ester, ketone, or aldehyde) is subject to facile hydration in the active site of a zinc hydrolase as long as the carbonyl is isosteric with that of the natural substrate.
“Thus, any carbonyl, whether that of a peptide, ester, ketone, or aldehyde, is subject to facile hydration in the active site of a zinc hydrolase as long as the carbonyl is isosteric with that of the natural substrate.”
Quote in the paperSubstantial claim - Interpretationreasoning
Interaction with the L1 loop appears more important for binding to HDACs 1-3 than to HDAC6.
“The short, bulky linker of HPOB sterically precluded a closer approach of the hydroxamate group to Zn2+, which may also have prevented the “cap” moiety of HPOB from interacting with the L1 loop, an interaction that appears to be more important for binding to HDACs 1-3 than to HDAC6.”
Quote in the paperSubstantial claim - Interpretationown data
The studies illuminated the structural basis of substrate specificity and catalysis for the CD1 and CD2 domains of the class IIb deacetylase HDAC6.
“Our studies have illuminated the structural basis of substrate specificity and catalysis for the CD1 and CD2 domains of the class IIb deacetylase HDAC6.”
Quote in the paperSubstantial claim - Interpretationreasoning
The short, bulky linker of HPOB may prevent its cap moiety from interacting with the L1 loop.
“The short, bulky linker of HPOB sterically precluded a closer approach of the hydroxamate group to Zn2+, which may also have prevented the “cap” moiety of HPOB from interacting with the L1 loop, an interaction that appears to be more important for binding to HDACs 1-3 than to HDAC6.”
Quote in the paperSubstantial claim - Interpretationown data
HDAC6 CD1 and CD2 use new modes of peptide substrate recognition that contrast with substrate binding modes previously observed for HDAC8.
“In particular, we have demonstrated new modes of peptide substrate recognition by HDAC6 CD1 and CD2 that contrast with substrate binding modes previously observed for the well-studied class I isozyme HDAC8.”
Quote in the paperSubstantial claim - Interpretationown data
HDAC6 is an ideal receptor for in silico docking experiments.
“Additionally, the L1 and L2 loops flanking the active site are relatively rigid, as revealed in the 12 zCD2 structures reported herein, making HDAC6 an ideal receptor for in silico docking experiments.”
Quote in the paperSubstantial claim- Rests on an assumption: The inhibitor binding modes observed in zebrafish CD2 crystals are representative of human HDAC6.
- Interpretationreasoning
Since the Aoe side chain carbonyl is isosteric with the scissile carbonyl of acetyllysine, binding of Aoe-containing peptides to any HDAC should enable facile hydration of the Aoe ketone carbonyl, as observed in the zCD2-HC toxin complex.
“Since the carbonyl group of the Aoe side chain is isosteric with the scissile carbonyl of acetyllysine, the binding of Aoe-containing peptides to any HDAC should enable facile hydration of the Aoe ketone carbonyl, as observed in the zCD2-HC toxin complex.”
Quote in the paperSubstantial claim- Rests on an assumption: The Aoe side chain carbonyl is isosteric with the scissile carbonyl of acetyllysine.
- Study design and conductown data
Although Rmerge values were relatively high for some datasets, analysis of CC1/2 values indicated that these datasets were of sufficient quality for satisfactory structure determination and refinement.
“Although Rmerge values were relatively high for some datasets, analysis of CC1/2 values indicated that these datasets were of sufficient quality for satisfactory structure determination and refinement.”
Quote in the paperSubstantial claim
- May combine two claims. 53
- Classified as probably not a substantial claim. 9
May combine two claims.
PremisecitationHC toxin inhibits maize HD1-B, a class I HDAC, irreversibly but inhibits HD1-A, a class II HDAC, reversibly.
“HC toxin exhibits irreversible inhibition against maize HD1-B (a class I HDAC), but reversible inhibition against HD1-A (a class II HDAC).39”
Quote in the paperSubstantial claim1 of 1 sources checked- cites [39] Brosch, G., Ransom, R., Lechner, T., Walton, J.D. & Loidl, P. Inhibition of maize histone deacetylases by HC toxin, the host-selective toxin of Cochliobolus carbonum. Plant Cell 7, 1941–1950 (1995). source
The Abstract (p. 1941) says HD1-A and HD1-B were similarly inhibited by HC toxin and describes the inhibition as reversible. That contradicts the claimed irreversible inhibition of HD1-B. The passage does not assign either enzyme to an HDAC class. (LLM, conf=0.89)
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measured
May combine two claims.
PremisecitationTrapoxin contains the Aoe moiety and irreversibly inhibits HDAC1 but reversibly inhibits HDAC6.
“trapoxin contains the Aoe moiety and is a potent irreversible inhibitor of HDAC1, but it is a reversible inhibitor of HDAC6.40”
Quote in the paperSubstantial claim1 of 1 sources checked- cites [40] Furumai, R. et al. Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin. Proc. Natl. Acad. Sci. USA 98, 87–92 (2001). source
Probably not a substantial claim: may not pass S3 (load-bearing).
Study design and conductcitationThe quality of each model was verified with PROCHECK and MolProbity.
“The quality of each model was verified with PROCHECK55 and MolProbity.56”
Quote in the paperNot a substantial claim1 of 2 sources checked- cites [55] Laskowski, R.A., MacArthur, M.W., Moss, D.S. & Thornton, J.M. PROCHECK: A program to check the stereochemical quality of protein structures. J. Appl. Crystallogr. 26, 283–291 (1993). source
- cites [56] Chen, V.B. et al. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr. D Biol. Crystallogr. 66, 12–21 (2010). source
May combine two claims.
PremisecitationHPOB potency against HDAC6 is comparable to SAHA-like inhibitors, but its potency against other isozymes is significantly reduced.
“Accordingly, the potency of HPOB against HDAC6 is comparable to SAHA-like inhibitors, but HPOB potency against other isozymes is significantly reduced.43”
Quote in the paperSubstantial claim1 of 1 sources checked- cites [43] Lee, J.H. et al. Development of a histone deacetylase 6 inhibitor and its biological effects. Proc. Natl. Acad. Sci. USA 110, 15704–15709 (2013). source
May combine two claims.
Findingown dataWith substrates 9 and 10, hCD1 in Y782F hCD12 has a catalytic efficiency of about 1,000 M−1s−1, which is robust compared with hCD2 in Y386F hCD12.
“hCD1 (Y782F hCD12) exhibited robust catalytic efficiency (~1,000 M−1s−1) compared to hCD2 (Y386F hCD12) with substrates 9 and 10”
Quote in the paperSubstantial claimMay combine two claims.
Findingown datazCD1 is less active than zCD2, with kcat/KM reduced 21-fold for substrate 1 and 7-fold for substrate 8.
“zCD1 was less active than zCD2 (kcat/KM is reduced 21-fold and 7-fold for substrates 1 and 8, respectively).”
Quote in the paperNot a substantial claimMay combine two claims.
Findingown dataThe electron density map shows the scissile acetyllysine carbonyl attacked by a water molecule activated by H573 and Zn2+, forming a tetrahedral intermediate that is trapped because H574 is absent.
“The electron density map indicated that the scissile carbonyl of acetyllysine underwent nucleophilic attack by a water molecule activated by H573 and Zn2+ to yield a tetrahedral intermediate, trapped in the active site due to the loss of the general acid H574”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataIn Y782F hCD12, hCD1 is catalytically active with C-terminal acetyllysine substrates 9 and 10 and is strictly specific for substrates with a C-terminal acetyllysine.
“significant hCD1 activity in Y782F hCD12 was observed with C-terminal acetyllysine peptide substrates 9 and 10, indicating that hCD1 was indeed catalytically active, but exhibited strict substrate specificity for substrates bearing C-terminal acetyllysine residues”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataThe 1.82 Å enzyme-substrate complex shows the scissile acetyllysine carbonyl binding to the previously vacant Zn2+ site without displacing the Zn2+-bound water, giving a pentacoordinate metal ion ready for catalysis.
“The 1.82 Å-resolution structure of the enzyme-substrate complex revealed that the scissile carbonyl of acetyllysine coordinates to the formerly vacant site on Zn2+ without displacing the Zn2+-bound water molecule, resulting in a pentacoordinate metal ion poised for catalysis”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataBoth hCD2 and zCD2 have broad substrate specificity.
“both hCD2 and zCD2 exhibited broad substrate specificity.”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataIn the zCD2 active site, only N530 and N645 are not conserved and correspond to D567 and M682 in hCD2; these residues lie at the outer rim and far from bound inhibitors.
“In the zCD2 active site, only N530 and N645 were not conserved, appearing as D567 and M682 in hCD2; moreover, these residues were at the outer rim of the active site and were quite distant from bound inhibitors.”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataThe hCD2 structure as a maltose-binding-protein fusion resembles the zCD2 structure, with 59% sequence identity and 75% similarity and an r.m.s. deviation of 0.43 Å over 314 Cα atoms.
“The crystal structure of hCD2 as a fusion construct with maltose binding protein was similar to that of zCD2 (59%/75% sequence identity/similarity) (Supplementary Fig. 5), with an r.m.s. deviation of 0.43 Å for 314 Cα atoms”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataIn the tetrahedral intermediate, O1 is stabilized by Zn2+ coordination at 2.1 Å and by a hydrogen bond to Y745, while O2 is 2.6 Å from Zn2+ and hydrogen bonds to H573.
“oxyanion atom O1 is stabilized by coordination to Zn2+ (2.1 Å) and a hydrogen bond with Y745; hydroxyl group O2 is somewhat distant from Zn2+ for inner sphere coordination (2.6 Å), but hydrogen bonds with H573.”
Quote in the paperSubstantial claimMay combine two claims.
Findingown datahCD1 hydrolyzes C-terminal acetyllysine substrates only when the tandem domain assembly is intact; the isolated hCD1 domain is inactive.
“The hydrolysis of C-terminal acetyllysine substrates by hCD1 required an intact tandem domain assembly, since hCD1 was not catalytically active as an isolated domain.”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataThe isolated hCD2 domain is about fivefold less active than hCD12, and no activity is detected for hCD1 up to 5 μM protein.
“The individual hCD2 domain was slightly less active (5-fold) than hCD12, whereas no activity was detected with hCD1 at up to 5 μM protein.”
Quote in the paperSubstantial claimMay combine two claims.
Findingown datazCD1 matches zCD2 activity on substrates 9 and 10 but is less active on substrates 11-13, with kcat/KM reduced 20-380-fold.
“zCD1 was as active as zCD2 with substrates 9 and 10, but less active than zCD2 with substrates 11–13 (20–380-fold reduced kcat/KM).”
Quote in the paperNot a substantial claimMay combine two claims.
Findingown dataMutating hCD1 does not substantially change catalysis, but mutating hCD2 nearly eliminates catalytic activity.
“showing that mutation of hCD1 does not significantly affect catalysis, whereas mutation of hCD2 essentially abolished catalytic activity.”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataCrystal structures were determined for human HDAC6 CD2 and for zebrafish HDAC6 CD1 and CD2.
“We now report the crystal structures of CD2 from Homo sapiens and CD1 and CD2 from Danio rerio HDAC6”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataBoth catalytic domains of zebrafish HDAC6 are active with fluorogenic substrates, including when each domain is assayed alone.
“both catalytic domains of zHDAC6 were active when assayed with fluorogenic substrates, even when assayed as individual domains.”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataIn full-length human and zebrafish enzymes, CD2 accepts endo- and exo-acetyllysine substrates X-K(Ac)-X, X-K(Ac)-Pro-X, and X-K(Ac)-CO2−, while hCD1 is strictly specific for exo-acetyllysine substrates X-K(Ac)-CO2− and zCD1 is somewhat less strict.
“in the full-length human and zebrafish enzymes, CD2 exhibited broad substrate specificity for endo- and exo-acetyllysine peptide substrates X-K(Ac)-X, X-K(Ac)-Pro-X, and X-K(Ac)-CO2−, whereas hCD1 exhibited strict substrate specificity for exo-acetyllysine peptide substrates X-K(Ac)-CO2−; substrate specificity for zCD1 was somewhat more relaxed.”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataThe gem-diol binds like the tetrahedral intermediate with substrate 8, with asymmetric Zn2+-O1 and Zn2+-O2 distances of 2.0 Å and 2.5 Å.
“The binding of the gem-diol moiety was comparable to that observed for the binding of the tetrahedral intermediate with substrate 8, making asymmetric metal coordination interactions with Zn2+-O1 and Zn2+-O2 distances of 2.0 Å and 2.5 Å, respectively.”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataMutating zCD2 N530 or hCD2 D567 does not significantly change activity, while mutating hCD2 S568 or zCD2 S531 lowers catalytic efficiency by 10-fold and 258-fold, respectively.
“mutations of zCD2 N530 and hCD2 D567 did not significantly affect activity, whereas mutations of hCD2 S568 and zCD2 S531 decreased catalytic efficiency by 10-fold and 258-fold, respectively.”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataH82F/F202Y zCD1 loses activity on endo-acetyllysine substrate 8 and becomes significantly specific for substrates 9 and 10, which have an exo-acetyllysine group.
“These amino acid substitutions abolished activity with endo-acetyllysine peptide substrate 8 (Fig. 1b) and conferred significant specificity for substrates 9 and 10, which bear an exo-acetyllysine group”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataThe zCD1 active site is slightly more constricted, partly because K330 protrudes, hydrogen bonds to the TSA cap carbonyl, and sterically pushes it toward the L1 loop.
“In zCD1, the active site was slightly more constricted, due in part to the protruding side chain of K330, which donates a hydrogen bond to the carbonyl group of the “cap” moiety of TSA and sterically displaces it toward the L1 loop.”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataHDAC6 zCD2, but not HDAC8, shows significant catalytic activity on substrates with Lys(Ac)-Pro linkages.
“we observed significant catalytic activity for HDAC6 zCD2, but not HDAC8, using substrates with Lys(Ac)-Pro linkages”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataThe Aoe ketone carbonyl is hydrated, so the inhibitor binds as a gem-diol(ate), similar to the trifluoroketone and the tetrahedral intermediate with substrate 8.
“the ketone carbonyl of Aoe was hydrated so that the inhibitor binds as a gem-diol(ate), much like that observed for the trifluoroketone (Supplementary Fig. 6c) or for the tetrahedral intermediate with substrate 8 (Fig. 2c).”
Quote in the paperSubstantial claimMay combine two claims.
Findingown datazCD1 and hCD1 have low or no activity on traditional fluorogenic substrates 1-8 but are highly specific for hydrolyzing exo-acetyllysine substrates 9 and 10, X-K(Ac)-CO2−.
“zCD1 and hCD1 exhibited low or no activity when assayed with traditional fluorogenic substrates 1–8, but instead were very specific for the hydrolysis of exo-acetyllysine substrates 9 and 10, X-K(Ac)-CO2−”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataIn addition to K353, two substitutions further constrict the hCD1 active site: zCD1 F202 and H82 correspond to hCD1 Y225 and F105.
“Two amino acid substitutions further constrict the active site of hCD1 in addition to K353 (which corresponds to K330 of zCD1): F202 and H82 in zCD1 (Fig. 4a) appear as Y225 and F105 in hCD1.”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataO1 hydrogen bonds with Y745, and O2 hydrogen bonds with H573 and H574.
“O1 formed a hydrogen bond with Y745, and O2 formed a hydrogen bond with H573 and H574.”
Quote in the paperNot a substantial claimMay combine two claims.
Findingown dataIn broad-specificity inhibitor complexes, the hydroxamate OH interacts with H573 and the hydroxamate C=O interacts with Y745.
“Additionally, the hydroxamate groups of all broad-specificity inhibitors tended toward bidentate Zn2+ coordination (Fig. 5b and Supplementary Table 5), displacing the Zn2+-bound water molecule of the resting enzyme, with the hydroxamate OH and C=O groups additionally interacting with H573 and Y745, respectively.”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataThe L-Ala-D-Ala and L-Aoe-D-Pro linkages of HC toxin are cis, giving the cyclic tetrapeptide an unusual alternating cis-trans-cis-trans geometry.
“the L-Ala–D-Ala and the L-Aoe–D-Pro peptide linkages of HC toxin adopted cis configurations, giving the cyclic tetrapeptide unusual alternating cis-trans-cis-trans peptide bond geometry.”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataIn zCD2, N530 is offset so that S531 aligns with HDAC8 D101 and accepts a hydrogen bond from the acetyllysine backbone NH in substrates 1 and 8.
“the corresponding residue in zCD2, N530, was offset such that S531 of zCD2 structurally aligned with D101 of HDAC8 and accepted a hydrogen bond from the backbone NH group of acetyllysine in substrates 1 and 8”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataThe corresponding residue in zCD2 is L712, which protrudes less into the active site.
“The corresponding residue in zCD2 was L712, which does not protrude as far into the active site.”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataSubstrate binding to zCD2 causes no major conformational changes in the L1 and L2 loops around the active site, so the active site is essentially pre-formed.
“substrate binding to zCD2 does not trigger any major conformational changes in the L1 and L2 loops surrounding the active site, so the active site is essentially pre-formed for substrate binding”
Quote in the paperNot a substantial claimMay combine two claims.
FindingcitationA trifluoroketone inhibitor binds as a tetrahedral gem-diol with Ki = 0.8 μM, mimicking the tetrahedral intermediate.
“The tetrahedral intermediate was also mimicked by the binding of a trifluoroketone inhibitor35 as a tetrahedral gem-diol with Ki = 0.8 μM”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [35] Decroos, C., Bowman, C.M. & Christianson, D.W. Synthesis and evaluation of N8-acetylspermidine analogues as inhibitors of bacterial acetylpolyamine amidohydrolase. Bioorg. Med. Chem. 21, 4530–4540 (2013). source
May combine two claims.
Findingown dataThis residue is P519 in zCD2 and does not cause a conformational change in the corresponding tryptophan W459.
“This residue appeared as P519 in zCD2 and did not trigger a conformational change of the corresponding tryptophan residue, W459.”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataBinding of HC toxin to zCD2, with Ki = 0.35 μM, causes no major conformational changes in HDAC6.
“No major conformational changes of HDAC6 accompanied the binding of HC toxin to zCD2 (Ki = 0.35 μM)”
Quote in the paperNot a substantial claimMay combine two claims.
Findingown dataAoe O1 coordinates to Zn2+ at 2.0 Å and hydrogen bonds with Y745; O2 weakly coordinates to Zn2+ at 2.5 Å and hydrogen bonds with H573 and H574.
“the Aoe O1 atom coordinates to Zn2+ (2.0 Å) and hydrogen bonds with Y745; the O2 atom makes a weak coordination interaction with Zn2+ (2.5 Å), and hydrogen bonds with H573 and H574.”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataThe hydroxamate group of HPOB coordinates to Zn2+ only through its OH group and does not displace the Zn2+-bound water molecule.
“In contrast, the hydroxamate group of the HDAC6-selective inhibitor HPOB (Ki = 1.0 nM) coordinated to Zn2+ only through its OH group, and it did not displace the Zn2+-bound water molecule; the Zn2+ ion is pentacoordinate with square pyramidal geometry (Fig. 5c).”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataThe product acetate anion binds with similar interactions, with Zn2+-O1 and Zn2+-O2 distances of 2.2 Å and 2.1 Å.
“similar interactions were observed for the binding of the product acetate anion with Zn2+-O1 and Zn2+-O2 distances of 2.2 Å and 2.1 Å, respectively”
Quote in the paperNot a substantial claimMay combine two claims.
Findingown dataThe Aoe backbone NH hydrogen bonds to S531, and water-mediated hydrogen bond networks connect the Aoe backbone carbonyl to H614 and the HC toxin L-Ala backbone NH to H463.
“The backbone NH group of Aoe donated a hydrogen bond to S531, and water-mediated hydrogen bond networks were observed between the backbone carbonyl of Aoe and H614, and the backbone NH group of HC toxin L-Ala and H463”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataY225F/Y782F hCD12 has nearly 100-fold higher activity on endo-acetyllysine fluorogenic substrates than hCD12 Y782F, while K353L/Y782F hCD12 has a more modest 10-fold increase.
“Y225F/Y782F hCD12 exhibited nearly 100-fold enhanced activity with endo-acetyllysine fluorogenic substrates when compared to hCD12 Y782F, whereas K353L/Y782F hCD12 exhibited a more modest 10-fold activity enhancement”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataThe CD2 domains of human and zebrafish HDAC6 can accommodate proline at the +1 position relative to the scissile acetyllysine residue, whereas HDAC8 cannot because of the hydrogen bond between D101 and the backbone NH of the +1 residue.
“The CD2 domains of human and zebrafish HDAC6 can accommodate proline at the +1 position relative to the scissile acetyllysine residue, whereas HDAC8 cannot based on the hydrogen bond between D101 and the backbone NH of the +1 residue.”
Quote in the paperSubstantial claimMay combine two claims.
Interpretationown dataH573 may act as a general base helping Zn2+ activate the nucleophilic water, so the two histidines in the zCD2 active site may have separate general base and general acid roles.
“H573 could serve as a general base to assist Zn2+ in activating the nucleophilic water molecule, so the tandem histidines in the HDAC6 zCD2 active site may serve separate general base-general acid functions.”
Quote in the paperSubstantial claimMay combine two claims.
PremisecitationHDAC6 removes the acetyl group from K40 of α-tubulin and thereby controls microtubule dynamics.
“HDAC6 catalyzes the deacetylation of K40 in the α-tubulin subunit of the microtubule,24 thereby regulating microtubule dynamics”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [24] Hubbert, C. et al. HDAC6 is a microtubule-associated deacetylase. Nature 417, 455–458 (2002). source
Probably not a substantial claim: may not pass S4 (based).
Premisenone givenHDAC6 is an important drug target because it contributes to oncogenic transformation and cancer metastasis.
“Histone deacetylase 6 (HDAC6) is a critical target for drug design due to its role in oncogenic transformation and cancer metastasis”
Quote in the paperNot a substantial claimMay combine two claims.
PremisecitationBlocking HDAC6 increases α-tubulin acetylation and suppresses microtubule dynamics, whereas having more HDAC6 lowers tubulin acetylation and raises cell motility.
“HDAC6 inhibition leads to hyperacetylation of α-tubulin and suppression of microtubule dynamics, while overexpression of HDAC6 reduces tubulin acetylation levels and increases cell motility.25”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [25] Szyk, A. et al. Molecular basis for age-dependent microtubule acetylation by tubulin acetyltransferase. Cell 157, 1405–1415 (2014). source
Probably not a substantial claim: may not pass S1 (asserted).
InterpretationreasoningK330 may act as a gatekeeper that gives specificity for C-terminal acetyllysine substrates by hydrogen bonding to the acetyllysine α-carboxylate.
“we hypothesized that K330 is a “gatekeeper” that confers specificity toward C-terminal acetyllysine substrates by hydrogen bonding with the α-carboxylate group of acetyllysine.”
Quote in the paperNot a substantial claimMay combine two claims.
InterpretationreasoningSubstrate 8 probably stays bound as a metastable tetrahedral intermediate because enzymes generally bind transition-state-like structures more favorably than substrate-like structures.
“Substrate 8 likely remained bound as a metastable tetrahedral intermediate because an enzyme generally favors the binding of a transition state-like structure over the binding of a substrate-like structure”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S1 (asserted). May combine two claims.
Interpretationown dataY202's hydroxyl may hydrogen bond to the acetyllysine α-carboxylate to prevent endo-acetyllysine binding, so that K330 and Y202, corresponding to hCD1 K353 and Y225, enforce specificity for exo-acetyllysine substrates X-K(Ac)-CO2−.
“We hypothesized that the hydroxyl group of Y202 hydrogen bonds with the α-carboxylate group of the acetyllysine substrates to abolish the binding of endo-acetylysine substrates, such that both K330 and Y202 (K353 and Y225 in hCD1) enforce specificity for substrates bearing an exo-acetyllysine group, X-K(Ac)-CO2−”
Quote in the paperNot a substantial claimMay combine two claims.
Interpretationown dataIn H574A zCD2, the substrate carbonyl is activated enough for nucleophilic attack, but the tetrahedral intermediate cannot collapse because H574 is missing to protonate the leaving amino group.
“the substrate carbonyl was sufficiently activated to undergo nucleophilic attack, but the resulting tetrahedral intermediate was locked in place, deep in the active site pocket – it could not collapse without general acid H574 to protonate the leaving amino group.”
Quote in the paperSubstantial claimProbably not a substantial claim: may not pass S1 (asserted).
InterpretationreasoningThe L-Aoe-D-Pro-L-Ala fragment of HC toxin may partially mimic a substrate site in a reverse turn, such as X-Lys(Ac)-Pro-X, or other proline-containing loops or cis-Lys(Ac)-X segments.
“we hypothesize that the L-Aoe-D-Pro-L-Ala fragment of HC toxin partially mimics a potential substrate site located in a reverse turn, such as X-Lys(Ac)-Pro-X, as well as other proline-containing loop structures or segments containing cis-Lys(Ac)-X linkages.”
Quote in the paperNot a substantial claimMay combine two claims.
InterpretationreasoningThe stronger O1-Zn2+ interaction may mean O1 is ionized to an oxyanion, which would also be stabilized inductively by the nearby trifluoromethyl group.
“The stronger interaction of O1 with Zn2+ may indicate ionization to an oxyanion, which would also be inductively stabilized by the adjacent trifluoromethyl group.”
Quote in the paperNot a substantial claimMay combine two claims.
InterpretationreasoningThe amide bond after the scissile acetyllysine is not required for substrate binding to zCD2 and hCD2 because it makes no direct contacts with active site residues.
“we suggest that the amide bond following the scissile acetyllysine residue is dispensable for substrate binding to zCD2 and hCD2, since it makes no direct interactions with active site residues.”
Quote in the paperSubstantial claimMay combine two claims.
Interpretationown dataThe backbone amide group after acetyllysine hydrogen bonds only to water, suggesting that any amino acid, including proline, can occupy that position.
“The backbone amide group following acetyllysine hydrogen bonded only with a water molecule, suggesting that any amino acid – including proline – could be accommodated at this position.”
Quote in the paperSubstantial claimMay combine two claims.
Interpretationown dataComparison of different zCD2-inhibitor structures highlights the structural basis for HDAC6-specific inhibitor design, which exploits a previously unobserved Zn2+ coordination mode by the hydroxamate group of HPOB: inhibitor binding does not require displacement of Zn2+-bound water.
“Finally, comparison of different zCD2-inhibitor structures highlights the structural basis for HDAC6-specific inhibitor design, which exploits a previously unobserved Zn2+ coordination mode by the hydroxamate group of HPOB: inhibitor binding does not require displacement of Zn2+-bound water.”
Quote in the paperSubstantial claim- Rests on an assumption: The inhibitor binding modes observed in zebrafish CD2 crystals are representative of human HDAC6.
Probably not a substantial claim: may not pass S3 (load-bearing).
Study design and conductnone givenNo statistical methods were used to predetermine sample size.
“No statistical methods were used to predetermine sample size.”
Quote in the paperNot a substantial claimClassified as probably not a substantial claim. May combine two claims.
PremisecitationZinc hydrolases activate a substrate carbonyl group for direct nucleophilic attack by a water molecule using Zn2+ coordination and a hydrogen bond interaction to polarize the carbonyl group; the nucleophilic water molecule is activated by Zn2+ coordination and a general base.
“In general, zinc hydrolases activate a substrate carbonyl group for direct nucleophilic attack by a water molecule using Zn2+ coordination and a hydrogen bond interaction to polarize the carbonyl group; the nucleophilic water molecule is activated by Zn2+ coordination and a general base.44,45”
Quote in the paperSubstantial claim0 of 2 sources checkedProbably not a substantial claim: may not pass S3 (load-bearing).
Study design and conductnone givenAssays were performed in triplicate at room temperature.
“Assays were performed in triplicate at room temperature.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
Study design and conductown dataNo backbone torsion angles adopt disallowed conformations in any structure.
“No backbone torsion angles adopt disallowed conformations in any structure.”
Quote in the paperNot a substantial claim
The paper relies on this without support.
Before this study, no crystal structures of HDAC6 catalytic domains existed.
“Despite these unresolved structure-function relationships, no crystal structures of HDAC6 catalytic domains have been available until now.”
The paper relies on this without support.
The active site of a Zn2+ hydrolase is adapted to allow water to attack almost any carbonyl group and to stabilize the resulting tetrahedral species.
“The active site of a Zn2+ hydrolase has evolved to enable nucleophilic attack of water at virtually any carbonyl group, preferentially stabilizing the resulting tetrahedral species.”
The paper relies on this without support.
The inhibitor binding modes observed in zebrafish CD2 crystals are representative of human HDAC6.
“Finally, comparison of different zCD2-inhibitor structures highlights the structural basis for HDAC6-specific inhibitor design, which exploits a previously unobserved Zn2+ coordination mode by the hydroxamate group of HPOB: inhibitor binding does not require displacement of Zn2+-bound water.”
The paper relies on this without support.
The Aoe side chain carbonyl is isosteric with the scissile carbonyl of acetyllysine.
“Since the carbonyl group of the Aoe side chain is isosteric with the scissile carbonyl of acetyllysine, the binding of Aoe-containing peptides to any HDAC should enable facile hydration of the Aoe ketone carbonyl, as observed in the zCD2-HC toxin complex.”
The paper relies on this without support.
The active site geometry of class I HDACs is sufficiently similar to zCD2 that the nucleophile and inhibitor binding conclusions transfer.
“Presumably, inhibitor binding to class I HDAC active sites allows for a closer contact between the nucleophilic thiol and the electrophilic epoxide to enable covalent bond formation.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Recent work on HDAC6/inhibitor complexes demonstrates that L1 loop conformational stability is important for interactions of L1 loop residues with inhibitor capping groups to achieve HDAC6 selectivity inhibition.
“the recent work on HDAC6/inhibitor complexes demonstrate that L1 loop conformational stability is important for the interactions of L1 loop residues with inhibitors capping groups to achieve HDAC6 selectivity inhibition 42-46”
From Characterization of Histone Deacetylase 8 (HDAC8) Selective Inhibition Reveals Specific Active Site Structural and Functional Determinants (2018) · cites this paper as [42]
The Results section (‘HDAC6 inhibitor selectivity’; page unavailable) reports that inhibitor caps contact L1-loop residues, but identifies those inhibitors as broad-specificity. The Discussion (page unavailable) describes the L1 loop as relatively rigid, while attributing the structural basis for HDAC6-selective inhibition to HPOB’s distinct zinc-coordination mode. It does not establish that L1-loop rigidity enables cap interactions to achieve selectivity. (LLM, conf=0.87)
Experimental — accuracy not yet measuredSelective inhibition appears to rely on small structural differences between HDAC1-3 and HDAC6 and on small thermodynamic differences in selective inhibitor binding.
“Selective inhibition appears to rely on small structural differences between HDAC1-3 and HDAC6 and on small thermodynamic differences in selective inhibitor binding 42-46 .”
From Characterization of Histone Deacetylase 8 (HDAC8) Selective Inhibition Reveals Specific Active Site Structural and Functional Determinants (2018) · cites this paper as [42]
The Results section on HDAC6 inhibitor selectivity describes structural differences in how broad-specificity inhibitors and the HDAC6-selective inhibitor HPOB bind to HDAC6. It does not establish that selectivity relies on small structural differences between HDAC1–3 and HDAC6, or on small thermodynamic differences in inhibitor binding. (LLM, conf=0.85)
Experimental — accuracy not yet measuredHDAC6 catalytic domain CD1 has a conserved active site lysine gatekeeper that dictates specificity for carboxy-terminal acetyllysine substrates bearing a negatively charged α-carboxylate group.
“We recently reported the X-ray crystal structures of both catalytic domains (CDs) of HDAC6, showing that a conserved active site lysine serves as a gatekeeper in CD1, in that it dictates specificity for carboxy-terminal acetyllysine substrates bearing a negatively charged α-carboxylate group17.”
From Histone deacetylase 10 structure and molecular function as a polyamine deacetylase (2017) · cites this paper as [17]
HDAC10 is not an efficient lysine deacetylase compared with HDAC6.
“In comparison with its closest relative, the cytosolic isozyme HDAC6 (ref. 17), HDAC10 was clearly not an efficient lysine deacetylase.”
From Histone deacetylase 10 structure and molecular function as a polyamine deacetylase (2017) · cites this paper as [17]
D94 corresponds to acetyllysine binding residues D101 of hHDAC8 and S568 of hHDAC6 CD2.
“Interestingly, D94 corresponds to acetyllysine binding residues D101 of hHDAC8 and S568 of hHDAC6 CD2 (refs 17, 30, 31).”
From Histone deacetylase 10 structure and molecular function as a polyamine deacetylase (2017) · cites this paper as [17]
E274 of zHDAC10 is conserved in HDAC10 orthologues as a gatekeeper to establish specificity for a cationic substrate, just as gatekeeper K330 is conserved in zHDAC6 CD1 to establish specificity for an anionic substrate.
“Our enzymological and X-ray crystallographic results suggest that E274 of zHDAC10 is conserved in HDAC10 orthologues as a gatekeeper to establish specificity for a cationic substrate, just as gatekeeper K330 is conserved in the corresponding position of zHDAC6 CD1 to establish specificity for an anionic substrate17.”
From Histone deacetylase 10 structure and molecular function as a polyamine deacetylase (2017) · cites this paper as [17]
In zHDAC10, the 310-helix ηA2 provides the additional steric bulk; in hHDAC6 CD1, F105 and Y225 provide this steric bulk.
“In zHDAC10, the 310-helix ηA2 provides this steric bulk; in hHDAC6 CD1 (ref. 17), F105 and Y225 provide this steric bulk.”
From Histone deacetylase 10 structure and molecular function as a polyamine deacetylase (2017) · cites this paper as [17]
The AAT binding mode in HDAC10 is similar to that observed in APAH-AAT and zHDAC6 CD2-AAT complexes.
“This binding mode was similar to that observed in the APAH–AAT and zHDAC6 CD2–AAT complexes1729.”
From Histone deacetylase 10 structure and molecular function as a polyamine deacetylase (2017) · cites this paper as [17]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Substrate 1 complex is assigned to two different mutants
MinorThe crystallization method identifies the zCD2-substrate 1 complex as Y745F, but the structure-determination section repeatedly identifies it as Y785F. These are different residue numbers for the same reported complex.
“The Y745F zCD2–substrate 1 complex was crystallized using the sitting drop vapor diffusion method at 4 °C”
“Y785F zCD2-substrate 1 complex: 90.6% allowed, 8.7% additionally allowed”
Cites
UCSF Chimera—A visualization system for exploratory research and analysis
Pettersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S., Greenblatt, D. M., Meng, E. C., & Ferrin, T. E. (2004) · Journal of Computational Chemistry · doi:10.1002/jcc.20084 · Cited by 45,260 · cited 1× · see citing works
“57 The Ramachandran statistics for each model are as follows: zCD1-TSA complex: 90.3% allowed, 9.4% additionally allowed; zCD2-TSA complex: 91.6% allowed, 7.8% additionally allowed; MBP-hCD2-TSA complex: 88.5% allowed, 10.8% additionally allowed; unliganded zCD2: 91.1% allowed, 8.6% additionally…”
Influential[20] Processing of X-ray diffraction data collected in oscillation mode
Otwinowski, Z., & Minor, W. (1997) · Methods in Enzymology · doi:10.1016/s0076-6879(97)76066-x · Cited by 33,475 · see citing works
Features and development of Coot
Emsley, P., Lohkamp, B., Scott, W. G., & Cowtan, K. D. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910007493 · Cited by 27,510 · see citing works
PROCHECK: a program to check the stereochemical quality of protein structures
Laskowski, R. A., MacArthur, M. W., Moss, D. S., & Thornton, J. M. (1993) · Journal of Applied Crystallography · doi:10.1107/s0021889892009944 · Cited by 24,581 · cited 1× · see citing works
“The quality of each model was verified with PROCHECK 55 and MolProbity.”
<i>PHENIX</i> : a comprehensive Python-based system for macromolecular structure solution
Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., et al. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909052925 · Cited by 23,716 · see citing works
<i>Phaser</i> crystallographic software
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read, R. J. (2007) · Journal of Applied Crystallography · doi:10.1107/s0021889807021206 · Cited by 20,612 · cited 1× · see citing works
“51 For the structure of the zCD2–SAHA complex, a model of the HDAC4 catalytic domain in a closed-loop conformation (PDB entry 4CBT) 52 was used as the search probe for rotation and translation function calculations.”
<i>MolProbity</i> : all-atom structure validation for macromolecular crystallography
Chen, V. B., Arendall, W. B., Headd, J. J., Keedy, D. A., Immormino, R. M., Kapral, G. J., Murray, L. W., Richardson, J. S., & Richardson, D. C. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909042073 · Cited by 14,115 · see citing works
Yung-Chi, C., & Prusoff, W. H. (1973) · Biochemical Pharmacology · doi:10.1016/0006-2952(73)90196-2 · Cited by 12,922 · see citing works
Lysine acetylation targets protein complexes and co-regulates major cellular functions
Choudhary, C., Kumar, C., Gnad, F., Nielsen, M. L., Rehman, M., Walther, T. C., Olsen, J. V., & Mann, M. (2009) · Science · doi:10.1126/science.1175371 · Cited by 4,040 · cited 1× · see citing works
“2, 3).”
HDAC6 is a microtubule-associated deacetylase
Hubbert, C., Guardiola, A., Shao, R., Kawaguchi, Y., Ito, A., Nixon, A., Yoshida, M., Wang, X.-F., & Yao, T.-P. (2002) · Nature · doi:10.1038/417455a · Cited by 2,403 · cited 1× · see citing works
“…in the cytoplasm by serine/glutamate-rich repeat motifs, 23 HDAC6 catalyzes the deacetylation of K40 in the α -tubulin subunit of the microtubule, 24 thereby regulating microtubule dynamics: HDAC6 inhibition leads to hyperacetylation of α -tubulin and suppression of microtubule dynamics, while…”
Regulation of cellular metabolism by protein lysine acetylation
Zhao, S., Xu, W., Jiang, W., Yu, W., Lin, Y., Zhang, T., Yao, J., Zhou, L., Zeng, Y., Li, H., et al. (2010) · Science · doi:10.1126/science.1179689 · Cited by 1,910 · see citing works
An operational definition of epigenetics: Figure 1.Preprint
Berger, S. L., Kouzarides, T., Shiekhattar, R., & Shilatifard, A. (2009) · Genes & Development · doi:10.1101/gad.1787609 · Cited by 1,889 · see citing works
Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders
Falkenberg, K. J., & Johnstone, R. W. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4360 · Cited by 1,564 · see citing works
Kawaguchi, Y., Kovacs, J. J., McLaurin, A. C., Vance, J. M., Ito, A., & Yao, T. (2003) · Cell · doi:10.1016/s0092-8674(03)00939-5 · Cited by 1,529 · see citing works
Gregoretti, I., Lee, Y.-M., & Goodson, H. V. (2004) · Journal of Molecular Biology · doi:10.1016/j.jmb.2004.02.006 · Cited by 1,456 · see citing works
New and emerging HDAC inhibitors for cancer treatment
West, A. C., & Johnstone, R. W. (2014) · Journal of Clinical Investigation · doi:10.1172/jci69738 · Cited by 1,404 · cited 1× · see citing works
“Briefly, substrates and enzymes were diluted into HDAC assay buffer [ 11).”
Epigenetic protein families: a new frontier for drug discovery
Arrowsmith, C. H., Bountra, C., Fish, P. V., Lee, K., & Schapira, M. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3674 · Cited by 1,327 · see citing works
The growing landscape of lysine acetylation links metabolism and cell signalling
Choudhary, C., Weinert, B. T., Nishida, Y., Verdin, E., & Mann, M. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3841 · Cited by 1,324 · see citing works
Histone Deacetylase Inhibitors: Overview and Perspectives
Dokmanovic, M., Clarke, C., & Marks, P. A. (2007) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-0324 · Cited by 1,173 · cited 2× · see citing works
“58 Evaluation of specific activity of HDAC6 with nonfluorogenic peptide substrates 9–13 (Supplementary Fig.”
Acetylation: a regulatory modification to rival phosphorylation?
Kouzarides, T. (2000) · The EMBO Journal · doi:10.1093/emboj/19.6.1176 · Cited by 1,155 · see citing works
HDAC6 Regulates Hsp90 Acetylation and Chaperone-Dependent Activation of Glucocorticoid Receptor
Kovacs, J. J., Murphy, P. J. M., Gaillard, S., Zhao, X., Wu, J.-T., Nicchitta, C. V., Yoshida, M., Toft, D. O., Pratt, W. B., & Yao, T.-P. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.04.021 · Cited by 1,153 · cited 1× · see citing works
“25 Other HDAC6 substrates include Hsp90 26 and the microtubule-associated protein Tau, implicating HDAC6 in the pathology of Alzheimer’s disease.”
Haggarty, S. J., Koeller, K. M., Wong, J. C., Grozinger, C. M., & Schreiber, S. L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0430973100 · Cited by 1,066 · cited 1× · see citing works
“Initial studies indicated that both domains are catalytically active toward histone substrates, with only CD2 exhibiting tubulin deacetylase activity, 19,29 whereas subsequent studies suggested that only CD2 is catalytically active.”
Acetylation of Metabolic Enzymes Coordinates Carbon Source Utilization and Metabolic Flux
Wang, Q., Zhang, Y., Yang, C., Xiong, H., Lin, Y., Yao, J., Li, H., Xie, L., Zhao, W., Yao, Y., et al. (2010) · Science · doi:10.1126/science.1179687 · Cited by 1,008 · cited 4× · see citing works
“19,30 Fluorogenic peptide substrates 1 – 8 exhibited comparable trends in specific activity (Supplementary Fig.”
InfluentialAcetylation of Tau Inhibits Its Degradation and Contributes to Tauopathy
Min, S.-W., Cho, S.-H., Zhou, Y., Schroeder, S., Haroutunian, V., Seeley, W. W., Huang, E. J., Shen, Y., Masliah, E., Mukherjee, C., et al. (2010) · Neuron · doi:10.1016/j.neuron.2010.08.044 · Cited by 949 · cited 1× · see citing works
“27,28 Curiously, it is not clear that both CD1 and CD2 domains of HDAC6 are fully functional.”
50 years of protein acetylation: from gene regulation to epigenetics, metabolism and beyond
Verdin, E. M., & Ott, M. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3931 · Cited by 876 · cited 5× · see citing works
“58 Evaluation of specific activity of HDAC6 with nonfluorogenic peptide substrates 9–13 (Supplementary Fig.”
InfluentialMolecular Architecture and \nBiological Reactions
Pauling, L. C. (1946) · CaltechAUTHORS (California Institute of Technology) · Cited by 865 · see citing works
Three proteins define a class of human histone deacetylases related to yeast Hda1p
Grozinger, C. M., Hassig, C. A., & Schreiber, S. L. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.9.4868 · Cited by 770 · cited 2× · see citing works
“19,30 Fluorogenic peptide substrates 1 – 8 exhibited comparable trends in specific activity (Supplementary Fig.”
The acetylation of tau inhibits its function and promotes pathological tau aggregation
Cohen, T. J., Guo, J. L., Hurtado, D. E., Kwong, L. K., Mills, I. P., Trojanowski, J. Q., & Lee, V. M. Y. (2011) · Nature Communications · doi:10.1038/ncomms1255 · Cited by 724 · cited 1× · see citing works
“27,28 Curiously, it is not clear that both CD1 and CD2 domains of HDAC6 are fully functional.”
Structural basis of the action of thermolysin and related zinc peptidases
Matthews, B. W. (1988) · Accounts of Chemical Research · doi:10.1021/ar00153a003 · Cited by 687 · cited 1× · see citing works
“44,45 Thus, any carbonyl, whether that of a peptide, ester, ketone, or aldehyde, is subject to facile hydration in the active site of a zinc hydrolase as long as the carbonyl is isosteric with that of the natural substrate.”
Writers and Readers of Histone Acetylation: Structure, Mechanism, and InhibitionPreprint
Marmorstein, R., & Zhou, M. (2014) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a018762 · Cited by 643 · cited 2× · see citing works
“However, significant hCD1 activity in Y782F hCD12 was observed with C-terminal acetyllysine peptide substrates 9 and 10 , indicating that hCD1 was indeed catalytically active, but exhibited strict substrate specificity for substrates bearing C-terminal acetyllysine residues (Fig.”
Christianson, D. W., & Lipscomb, W. N. (1989) · Accounts of Chemical Research · doi:10.1021/ar00158a003 · Cited by 606 · see citing works
Self-citationDelcuve, G. P., Khan, D. H., & Davie, J. R. (2012) · Clinical Epigenetics · doi:10.1186/1868-7083-4-5 · Cited by 505 · see citing works
Furumai, R., Komatsu, Y., Nishino, N., Khochbin, S., Yoshida, M., & Horinouchi, S. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.1.87 · Cited by 412 · cited 2× · see citing works
“39,40 The carbonyl group of the Aoe side chain is isosteric with the carbonyl group of acetyllysine, and the adjacent epoxide moiety is a potent electrophile capable of covalently modifying a suitably positioned nucleophile in HDAC active sites.”
Signaling Network Model of Chromatin
Schreiber, S. L., & Bernstein, B. (2002) · Cell · doi:10.1016/s0092-8674(02)01196-0 · Cited by 395 · cited 1× · see citing works
“32 Despite these unresolved structure-function relationships, no crystal structures of HDAC6 catalytic domains have been available until now.”
Structure, mechanism, and inhibition of histone deacetylases and related metalloenzymes
Lombardi, P. M., Cole, K., Dowling, D., & Christianson, D. W. (2011) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2011.08.004 · Cited by 279 · see citing works
Self-citationVannini, A., Volpari, C., Gallinari, P., Jones, P., Mattu, M., Carfí, A., De Francesco, R., Steinkühler, C., & Di Marco, S. (2007) · The EMBO Reports · doi:10.1038/sj.embor.7401047 · Cited by 256 · cited 1× · see citing works
“37,38 However, the corresponding residue in zCD2, N530, was offset such that S531 of zCD2 structurally aligned with D101 of HDAC8 and accepted a hydrogen bond from the backbone NH group of acetyllysine in substrates 1 and 8 (Fig.”
Crystal structures of fusion proteins with large‐affinity tags
Smyth, D. R., Mrozkiewicz, M. K., McGrath, W. J., Listwan, P., & Kobe, B. (2003) · Protein Science · doi:10.1110/ps.0243403 · Cited by 254 · see citing works
A New Family of Human Histone Deacetylases Related toSaccharomyces cerevisiae HDA1p
Fischle, W., Emiliani, S., Hendzel, M. J., Nagase, T., Nomura, N., Voelter, W., & Verdin, E. M. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.17.11713 · Cited by 225 · see citing works
Ouyang, H., Ali, Y., Ravichandran, M., Dong, A., Qiu, W., MacKenzie, F., Dhe‐Paganon, S., Arrowsmith, C. H., & Zhai, R. G. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.273730 · Cited by 221 · see citing works
Molecular Basis for Age-Dependent Microtubule Acetylation by Tubulin Acetyltransferase
Szyk, A., Deaconescu, A. M., Spector, J., Goodman, B., Valenstein, M. L., Ziolkowska, N. E., Kormendi, V., Grigorieff, N., & Roll-Mecak, A. (2014) · Cell · doi:10.1016/j.cell.2014.03.061 · Cited by 218 · cited 1× · see citing works
“25 Other HDAC6 substrates include Hsp90 26 and the microtubule-associated protein Tau, implicating HDAC6 in the pathology of Alzheimer’s disease.”
Brosch, G., Ransom, R., Lechner, T., Walton, J. D., & Loidl, P. (1995) · The Plant Cell · doi:10.1105/tpc.7.11.1941 · Cited by 204 · cited 2× · see citing works
“39,40 The carbonyl group of the Aoe side chain is isosteric with the carbonyl group of acetyllysine, and the adjacent epoxide moiety is a potent electrophile capable of covalently modifying a suitably positioned nucleophile in HDAC active sites.”
Dowling, D. P., Gantt, S. L., Gattis, S. G., Fierke, C. A., & Christianson, D. W. (2008) · Biochemistry · doi:10.1021/bi801610c · Cited by 200 · cited 1× · see citing works
“37,38 However, the corresponding residue in zCD2, N530, was offset such that S531 of zCD2 structurally aligned with D101 of HDAC8 and accepted a hydrogen bond from the backbone NH group of acetyllysine in substrates 1 and 8 (Fig.”
Self-citationTwo Catalytic Domains Are Required for Protein Deacetylation
Zhang, Y., Gilquin, B., Khochbin, S., & Matthias, P. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.c500241200 · Cited by 161 · cited 1× · see citing works
“30 While both domains may be required for activity, 31 it is possible that CD1 could serve as a microtubule binding domain.”
Structural Basis for Sirtuin Activity and Inhibition
Yuan, H., & Marmorstein, R. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.r112.372300 · Cited by 160 · see citing works
Role of the Tetradecapeptide Repeat Domain of Human Histone Deacetylase 6 in Cytoplasmic Retention
Bertos, N., Gilquin, B., Chan, G. K. T., Yen, T. J., Khochbin, S., & Yang, X. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m408583200 · Cited by 160 · cited 1× · see citing works
“Anchored in the cytoplasm by serine/glutamate-rich repeat motifs, 23 HDAC6 catalyzes the deacetylation of K40 in the α -tubulin subunit of the microtubule, 24 thereby regulating microtubule dynamics: HDAC6 inhibition leads to hyperacetylation of α -tubulin and suppression of microtubule dynamics,…”
Bürli, R. W., Luckhurst, C. A., Aziz, O., Matthews, K. L., Yates, D., Lyons, K. A., Beconi, M., McAllister, G., Breccia, P., Stott, A. J., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm4011884 · Cited by 153 · cited 1× · see citing works
“51 For the structure of the zCD2–SAHA complex, a model of the HDAC4 catalytic domain in a closed-loop conformation (PDB entry 4CBT) 52 was used as the search probe for rotation and translation function calculations.”
HDAC6 Deacetylates and Ubiquitinates MSH2 to Maintain Proper Levels of MutSα
Zhang, M., Xiang, S., Joo, H.-Y., Wang, L., Williams, K. A., Liu, W., Hu, C., Tong, D., Haakenson, J., Wang, C., et al. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.04.028 · Cited by 151 · see citing works
Characterization of the two catalytic domains in histone deacetylase 6
Zou, H., Wu, Y., Navre, M., & Sang, B. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.12.144 · Cited by 144 · cited 1× · see citing works
“30 While both domains may be required for activity, 31 it is possible that CD1 could serve as a microtubule binding domain.”
Development of a histone deacetylase 6 inhibitor and its biological effects
Lee, J.-H., Mahendran, A., Yao, Y., Ngo, L., Venta-Perez, G., Choy, M. L., Kim, N., Ham, W.-S., Breslow, R., & Marks, P. A. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1313893110 · Cited by 141 · cited 1× · see citing works
“43”
Liang, T. C., & Abeles, R. H. (1987) · Biochemistry · doi:10.1021/bi00398a011 · Cited by 138 · cited 1× · see citing works
“36 Additionally, O1 formed a hydrogen bond with Y745, and O2 formed a hydrogen bond with H573 and H574.”
Mechanism of carboxypeptidase A: hydration of a ketonic substrate analogue.
Christianson, D. W., David, P. R., & Lipscomb, W. N. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.6.1512 · Cited by 71 · cited 1× · see citing works
“…such hydration behavior was first observed for the binding of unactivated aldehyde-and ketone-based substrate analogues to carboxypeptidase A. 41,42 The active site of a Zn 2+ hydrolase has evolved to enable nucleophilic attack of water at virtually any carbonyl group, preferentially…”
Self-citationKobe, B., Wilson, K. A., Teh, T., et al. (1998) · Protein Science · doi:10.1002/pro.5560070715 · Cited by 69 · see citing works
Norvell, A., & McMahon, S. B. (2010) · Science · doi:10.1126/science.1187159 · Cited by 69 · see citing works
Decroos, C., Bowman, C. M., Moser, J. S., Christianson, K. E., Deardorff, M. A., & Christianson, D. W. (2014) · ACS Chemical Biology · doi:10.1021/cb5003762 · Cited by 67 · see citing works
Self-citationGeneral Base–General Acid Catalysis in Human Histone Deacetylase 8
Gantt, S. M. L., Decroos, C., Lee, M. S., Gullett, L. E., Bowman, C. M., Christianson, D. W., & Fierke, C. A. (2016) · Biochemistry · doi:10.1021/acs.biochem.5b01327 · Cited by 67 · cited 1× · see citing works
“33 In H574A zCD2, the substrate carbonyl was sufficiently activated to undergo nucleophilic attack, but the resulting tetrahedral intermediate was locked in place, deep in the active site pocket – it could not collapse without general acid H574 to protonate the leaving amino group.”
Self-citationSelective Histone Deacetylase Inhibitors with Anticancer Activity
Ma, N., Luo, Y., Wang, Y., Liao, C., Ye, W., & Jiang, S. (2015) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026615666150813145629 · Cited by 61 · see citing works
Binding of a possible transition state analogue to the active site of carboxypeptidase A.
Christianson, D. W., & Lipscomb, W. N. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.20.6840 · Cited by 59 · cited 1× · see citing works
“…such hydration behavior was first observed for the binding of unactivated aldehyde-and ketone-based substrate analogues to carboxypeptidase A. 41,42 The active site of a Zn 2+ hydrolase has evolved to enable nucleophilic attack of water at virtually any carbonyl group, preferentially…”
Self-citationHildmann, C., Ninković, M., Dietrich, R., Wegener, D., Riester, D., Zimmermann, T. P., Birch, O. M., Bernegger, C., Loidl, P., & Schwienhorst, A. (2004) · Journal of Bacteriology · doi:10.1128/jb.186.8.2328-2339.2004 · Cited by 52 · see citing works
Kinetics and thermodynamics of metal‐binding to histone deacetylase 8
Kim, B.-C., Pithadia, A. S., & Fierke, C. A. (2014) · Protein Science · doi:10.1002/pro.2623 · Cited by 17 · see citing works
Decroos, C., Bowman, C. M., & Christianson, D. W. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.05.045 · Cited by 17 · cited 1× · see citing works
“The tetrahedral intermediate was also mimicked by the binding of a trifluoroketone inhibitor 35 as a tetrahedral gem-diol with K i = 0.8 μM (Supplementary Fig.”
InfluentialSelf-citationMolecular Architecture and Biological Reactions
Pauling, L. C. (1946) · Chemical & Engineering News · doi:10.1021/cen-v024n010.p1375 · Cited by 9 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Indoles as therapeutics of interest in medicinal chemistry: Bird's eye view
Chadha, N., & Silakari, O. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.04.003 · Cited by 641 · see citing works
Milazzo, G., Mercatelli, D., Muzio, G. D., Triboli, L., Rosa, P. D., Perini, G., & Giorgi, F. M. (2020) · Genes · doi:10.3390/genes11050556 · Cited by 431 · see citing works
“However, more recent and thorough data have unquestionably shown that both domains are catalytically active with different substrate specificity: while CD2 exerts its activity on any acetyl-Lysine, CD1 shows preference for deacetylation of C-terminal acetyl-Lysine substrates [95].”
BackgroundLysine Acetylation Goes Global: From Epigenetics to Metabolism and Therapeutics
Ali, I., Conrad, R. J., Verdin, E. M., & Ott, M. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00181 · Cited by 366 · see citing works
The Roles of Histone Deacetylases and Their Inhibitors in Cancer Therapy
Guo, L., Tian, Y., & Zhu, W. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.576946 · Cited by 358 · see citing works
Acetylation of intrinsically disordered regions regulates phase separation
Saito, M., Heß, D., Eglinger, J., Fritsch, A. W., Kreysing, M., Weinert, B. T., Choudhary, C., & Matthias, P. (2018) · Nature Chemical Biology · doi:10.1038/s41589-018-0180-7 · Cited by 300 · see citing works
Targeting Metalloenzymes for Therapeutic Intervention
Chen, A. Y., Adamek, R. N., Dick, B. L., Credille, C. V., Morrison, C. N., & Cohen, S. M. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00201 · Cited by 277 · see citing works
HDAC6 as privileged target in drug discovery: A perspective
Pulya, S., Amin, S. A., Adhikari, N., Biswas, S., Jha, T., & Ghosh, B. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105274 · Cited by 265 · see citing works
ARID1A-mutated ovarian cancers depend on HDAC6 activity
Bitler, B. G., Wu, S., Park, P. H., Hai, Y., Aird, K. M., Wang, Y., Zhai, Y., Kossenkov, A. V., Vara-Ailor, A., Rauscher, F. J., et al. (2017) · Nature Cell Biology · doi:10.1038/ncb3582 · Cited by 232 · see citing works
Self-citationHistone deacetylase 10 structure and molecular function as a polyamine deacetylase
Hai, Y., Shinsky, S. A., Porter, N. J., & Christianson, D. W. (2017) · Nature Communications · doi:10.1038/ncomms15368 · Cited by 200 · see citing works
Self-citationMetal–ligand interactions in drug design
Riccardi, L., Genna, V., & Vivo, M. D. (2018) · Nature Reviews Chemistry · doi:10.1038/s41570-018-0018-6 · Cited by 202 · see citing works
Jenke, R., Reßing, N., Hansen, F. K., Aigner, A. M., & Büch, T. (2021) · Cancers · doi:10.3390/cancers13040634 · Cited by 194 · see citing works
“For the second catalytic do ain (C 2) of C6, the tunnel appears to be slightly ore spacious but shorter, hile the entrance area on the enzy e’s surface is larger co pared to other isofor s [46].”
BackgroundUnusual zinc-binding mode of HDAC6-selective hydroxamate inhibitors
Porter, N. J., Mahendran, A., Breslow, R., & Christianson, D. W. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1718823114 · Cited by 190 · see citing works
“”Our recent structural and functional studies demonstrate that zebrafish HDAC6 is a validated and more readily crystallized surrogate of human HDAC6, the actual drug target (27).”
BackgroundInfluentialSelf-citationMelatonin and sirtuins: A “not-so unexpected” relationship
Mayo, J. C., Sainz, R. M., González Menéndez, P., Cepas, V., Tan, D., & Reiter, R. J. (2017) · Journal of Pineal Research · doi:10.1111/jpi.12391 · Cited by 175 · see citing works
Tolomeu, H. V., & Fraga, C. A. M. (2023) · Molecules · doi:10.3390/molecules28020838 · Cited by 165 · see citing works
“We can also see the residue (H614) acting on the triad of amino acids responsible for sustaining the zinc atom (through the interaction η(1)(σ,Npy)) present in the catalytic site of the enzyme [7,65].”
BackgroundRecent advances in the discovery of potent and selective HDAC6 inhibitors
Wang, X.-X., Wan, R.-Z., & Liu, Z.-P. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.10.040 · Cited by 152 · see citing works
Structure, mechanism, and inhibition of the zinc-dependent histone deacetylases
Porter, N. J., & Christianson, D. W. (2019) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2019.01.004 · Cited by 146 · see citing works
Self-citationHistone deacetylase 11 is an ε-N-Myristoyllysine hydrolase
Moreno-Yruela, C., Galleano, I., Madsen, A. S., & Olsen, C. A. (2018) · Cell Chemical Biology · doi:10.1016/j.chembiol.2018.04.007 · Cited by 149 · see citing works
Zhang, X., Qin-Ma, Wu, H.-P., Khamis, M. Y., Li, Y., Ma, L., & Liu, H. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01782 · Cited by 160 · see citing works
Next-generation of selective histone deacetylase inhibitors
Yang, F., Zhao, N., Ge, D., & Chen, Y. (2019) · RSC Advances · doi:10.1039/c9ra02985k · Cited by 144 · see citing works
The Search for Potent, Small‐Molecule HDACIs in Cancer Treatment: A Decade After Vorinostat
Zagni, C., Floresta, G., Monciino, G., & Rescifina, A. (2017) · Medicinal Research Reviews · doi:10.1002/med.21437 · Cited by 138 · see citing works
Marek, M., Shaik, T. B., Heimburg, T., Chakrabarti, A., Lancelot, J., Ramos-Morales, E., Da Veiga, C., Kalinin, D., Melesina, J., Robaa, D., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01087 · Cited by 123 · see citing works
Strategies To Design Selective Histone Deacetylase Inhibitors
Melesina, J., Simoben, C. V., Praetorius, L., Bülbül, E. F., Robaa, D., & Sippl, W. (2021) · ChemMedChem · doi:10.1002/cmdc.202000934 · Cited by 118 · see citing works
Yang, K., Wu, H., Zhang, Z., Leisten, E. D., Nie, X., Liu, B., Wen, Z., Zhang, J., Cunningham, M. D., & Tang, W. (2020) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.0c00046 · Cited by 124 · see citing works
Porter, N. J., Osko, J. D., Diedrich, D., Kurz, T., Hooker, J. M., Hansen, F. K., & Christianson, D. W. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01013 · Cited by 111 · see citing works
Self-citationBrindisi, M., Saraswati, A. P., Brogi, S., Gemma, S., Butini, S., & Campiani, G. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00924 · Cited by 122 · see citing works
Vögerl, K., Ong, N., Senger, J., Herp, D., Schmidtkunz, K., Marek, M., Müller, M., Bartel, K., Shaik, T. B., Porter, N. J., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01090 · Cited by 104 · see citing works
Self-citationYao, L., Mustafa, N. B., Tan, E. C., Poulsen, A., Singh, P., Duong‐Thi, M., Lee, J. X. T., Ramanujulu, P. M., Chng, W. J., Yen, J. J. Y., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00678 · Cited by 111 · see citing works
Hosseinzadeh, P., Watson, P. R., Craven, T. W., Li, X., Rettie, S., Pardo‐Ávila, F., Bera, A. K., Mulligan, V. K., Lu, P., Ford, A. S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23609-8 · Cited by 94 · see citing works
Self-citationZhang, Y., Ying, J. B., Hong, J. J., Li, F., Fu, T. T., Yang, F. Y., Zheng, G. X., Yao, X., Lou, Y., Qiu, Y., et al. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00729 · Cited by 94 · see citing works
Géraldy, M. N. E., Morgen, M., Sehr, P. A., Steimbach, R. R., Moi, D., Ridinger, J., Oehme, I., Witt, O., Malz, M., Nogueira, M. S., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01936 · Cited by 96 · see citing works
A patent review of histone deacetylase 6 inhibitors in neurodegenerative diseases (2014-2019)
Shen, S., & Kozikowski, A. P. (2019) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2019.1708901 · Cited by 95 · see citing works
“Moreover, the crystal structures also reveal that certain capping or linker groups are able to engage in additional hydrogen bonds with key residues, such as S531, that play important roles in HDAC6 substrate recognition [27,29].”
BackgroundThakur, A., Tawa, G. J., Henderson, M. J., Danchik, C., Liu, S., Shah, P., Wang, A. Q., Dunn, G., Kabir, M., Padilha, E. C., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00193 · Cited by 106 · see citing works
HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors
Sangwan, R., Rajan, R., & Mandal, P. K. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.08.073 · Cited by 97 · see citing works
Heimburg, T., Kolbinger, F. R., Zeyen, P., Ghazy, E., Herp, D., Schmidtkunz, K., Melesina, J., Shaik, T. B., Erdmann, F., Schmidt, M., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01447 · Cited by 92 · see citing works
Shen, S., Hadley, M. M., Ustinova, K., Pavlı́ček, J., Knox, T. J., Noonepalle, S. K. R., Tavares, M. T., Zimprich, C., Zhang, G., Robers, M. B., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00946 · Cited by 85 · see citing works
Human histone deacetylase 6 shows strong preference for tubulin dimers over assembled microtubules
Skultetyova, L., Ustinova, K., Kutil, Z., Nováková, Z., Pavlı́ček, J., Mikesova, J., Trapl, D., Baranová, P., Havlínová, B., Hubálek, M., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-11739-3 · Cited by 82 · see citing works
Shen, S., Svoboda, M., Zhang, G., Cavasin, M. A., Motlova, L., McKinsey, T. A., Eubanks, J. H., Bařinka, C., & Kozikowski, A. P. (2020) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.9b00560 · Cited by 87 · see citing works
HDAC6 Brain Mapping with [18F]Bavarostat Enabled by a Ru-Mediated Deoxyfluorination
Strebl, M. G., Campbell, A. J., Zhao, W., Schroeder, F. A., Riley, M. M., Chindavong, P. S., Morin, T., Haggarty, S. J., Wagner, F. F., Ritter, T., et al. (2017) · ACS Central Science · doi:10.1021/acscentsci.7b00274 · Cited by 87 · see citing works
HDAC Inhibitors: Dissecting Mechanisms of Action to Counter Tumor Heterogeneity
Karagiannis, D., & Rampias, T. N. (2021) · Cancers · doi:10.3390/cancers13143575 · Cited by 84 · see citing works
Sellmer, A., Stangl, H., Beyer, M., Grünstein, E., Leonhardt, M., Pongratz, H., Eichhorn, E., Elz, S., Striegl, B., Jenei‐Lanzl, Z., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01593 · Cited by 80 · see citing works
Zeleke, T. Z., Pan, Q., Chiuzan, C. C., Onishi, M., Li, Y., Tan, H., Alvarez, M. J., Honan, E., Yang, M., Chia, P. L., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00489-5 · Cited by 84 · see citing works
Ubiquitin in Influenza Virus Entry and Innate Immunity
Rudnicka, A., & Yamauchi, Y. (2016) · Viruses · doi:10.3390/v8100293 · Cited by 77 · see citing works
“HDAC6 contains tand m catalytic domains CD1 and CD2, as well s, a ZnF-UBP [63,65,72].”
BackgroundOsko, J. D., & Christianson, D. W. (2019) · Biochemistry · doi:10.1021/acs.biochem.9b00934 · Cited by 81 · see citing works
Self-citationLi, Y., Sang, S., Ren, W., Pei, Y., Bian, Y., Chen, Y., & Sun, H. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113874 · Cited by 77 · see citing works
Binding of the Microbial Cyclic Tetrapeptide Trapoxin A to the Class I Histone Deacetylase HDAC8
Porter, N. J., & Christianson, D. W. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.7b00330 · Cited by 73 · see citing works
Self-citationDiscovery of the First-in-Class Dual Histone Deacetylase–Proteasome Inhibitor
Bhatia, S., Krieger, V., Groll, M., Osko, J. D., Reßing, N., Ahlert, H., Borkhardt, A., Kurz, T., Christianson, D. W., Hauer, J., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01487 · Cited by 78 · see citing works
Self-citationRodrigues, D. A., Pinheiro, P. D. S. M., Sagrillo, F. S., Bolognesi, M. L., & Fraga, C. A. M. (2020) · Medicinal Research Reviews · doi:10.1002/med.21701 · Cited by 72 · see citing works
Rabal, O., Sánchez-Arias, J. A., Cuadrado‐Tejedor, M., de Miguel, I., Pérez-González, M., García, C., Ugarte, A., de Mendoza, A. E., Sáez, E., Espelosin, M., et al. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.03.005 · Cited by 71 · see citing works
Curcio, A., Rocca, R., Alcaro, S., & Artese, A. (2024) · Pharmaceuticals · doi:10.3390/ph17050620 · Cited by 71 · see citing works
“…the identi fi ed HDACs, HDAC11 is the shortest, and is primarily comprised of the core catalytic domain that exhibits exclusive deacetylase activity [62]. the identified HDACs, HDAC11 is the shortest, and is primarily comprised of the core catalytic domain that exhibits exclusive deacetylase…”
Characterization of Histone Deacetylase Mechanisms in Cancer Development
Hai, R., He, L., Shu, G., & Yin, G. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.700947 · Cited by 67 · see citing works
“For example, HDAC6 can act as a a-tubulin deacetylase and participate in multiple cytoplasmic pathways related to microtubules (45, 46), revealing that it may be an important therapeutic for treating Alzheimer’s disease and cancer (47).”
BackgroundAttenuation of NLRP3 Inflammasome Activation by Indirubin-Derived PROTAC Targeting HDAC6
Cao, Z., Gu, Z., Lin, S., Chen, D., Wang, J., Zhao, Y., Li, Y., Liu, T., Li, Y., Wang, Y., et al. (2021) · ACS Chemical Biology · doi:10.1021/acschembio.1c00681 · Cited by 70 · see citing works
Histone deacetylase complexes: Structure, regulation and function
Asmamaw, M. D., He, A., Zhang, L., Liu, H., & Gao, Y. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189150 · Cited by 70 · see citing works
de Freitas, R. F., Harding, R., Franzoni, I., Ravichandran, M., Mann, M. K., Ouyang, H., Lautens, M., Santhakumar, V., Arrowsmith, C. H., & Schapira, M. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00258 · Cited by 69 · see citing works
Histone Deacetylases and Their Inhibitors in Cancer Epigenetics
Hassell, K. N. (2019) · Diseases · doi:10.3390/diseases7040057 · Cited by 64 · see citing works
“The three nuclear export signals are significant players in the functional characteristics of HDAC6 as a catalyzed nuclear–cytoplasmic pathway with targets unrelated to transcription [19].”
BackgroundExploring the inhibitory activity of valproic acid against the HDAC family using an MMGBSA approach
Sixto‐López, Y., Bello, M., & Correa‐Basurto, J. (2020) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-020-00304-2 · Cited by 61 · see citing works
“For the PDBs in which there were no co-crystallized ligands, a well-known selective ligand was used as indicated: HDAC1, Quisinostat [34]; HDAC2, AC1OCG0B [35]; HDAC3, RGFP966 [36]; HDAC4, TFMK [37], and as a selective HDAC4 compound, KEE [38]; HDAC6, Trichostatin A (TSA) [39]; HDAC7, TMP269 [11]; and HDAC8, APHA [40]…”
BackgroundMethodInfluentialMackwitz, M. K. W., Hamacher, A., Osko, J. D., Held, J., Schöler, A., Christianson, D. W., Kassack, M. U., & Hansen, F. K. (2018) · Organic Letters · doi:10.1021/acs.orglett.8b01118 · Cited by 68 · see citing works
Self-citationCao, Z., Yang, F., Wang, J., Gu, Z., Lin, S., Wang, P., An, J., Liu, T., Li, Y., Li, Y., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01311 · Cited by 71 · see citing works
Entropy as a Driver of Selectivity for Inhibitor Binding to Histone Deacetylase 6
Porter, N. J., Wagner, F. F., & Christianson, D. W. (2018) · Biochemistry · doi:10.1021/acs.biochem.8b00367 · Cited by 64 · see citing works
Self-citationYue, K., Sun, S., Jia, G., Qin, M., Hou, X., Chou, C. J., Huang, C., & Li, X. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00853 · Cited by 74 · see citing works
Simone, A. D., Pietra, V. L., Betari, N., Petragnani, N., Conte, M., Daniele, S., Pietrobono, D., Martini, C., Petralla, S., Casadei, R., et al. (2019) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.8b00507 · Cited by 58 · see citing works
Noonepalle, S. K. R., Shen, S., Ptáček, J., Tavares, M. T., Zhang, G., Stránský, J., Pavlı́ček, J., Ferreira, G. M., Hadley, M. M., Pelaez, G. D., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00567 · Cited by 61 · see citing works
Mozzetta, C., Sartorelli, V., & Puri, P. (2024) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2024.01.007 · Cited by 57 · see citing works
Vergani, B., Sandrone, G., Marchini, M., Ripamonti, C., Cellupica, E., Galbiati, E., Caprini, G., Pavich, G., Porro, G., Rocchio, I., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01194 · Cited by 56 · see citing works
Osko, J. D., & Christianson, D. W. (2020) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2020.127023 · Cited by 56 · see citing works
Self-citationSixto‐López, Y., Gómez-Vidal, J. A., de Pedro, N., Bello, M., Rosales‐Hernández, M. C., & Correa‐Basurto, J. (2020) · Scientific Reports · doi:10.1038/s41598-020-67112-4 · Cited by 54 · see citing works
Campiani, G., Cavella, C., Osko, J. D., Brindisi, M., Relitti, N., Brogi, S., Saraswati, A. P., Federico, S., Chemi, G., Maramai, S., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00184 · Cited by 62 · see citing works
Self-citationNew insights into the non-enzymatic function of HDAC6
Zhu, Y.-Z., Feng, M., Wang, B., Zheng, Y., Jiang, D., Zhao, L., Mamun, M., Kang, H., Nie, H., Zhang, X., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114438 · Cited by 55 · see citing works
Drugs/agents for the treatment of ischemic stroke: Advances and perspectives
Jia, J., Jiao, W., Wang, G., Wu, J., Huang, Z., & Zhang, Y. (2023) · Medicinal Research Reviews · doi:10.1002/med.22009 · Cited by 58 · see citing works
The Zinc-Binding Group Effect: Lessons from Non-Hydroxamic Acid Vorinostat Analogs
Geurs, S., Clarisse, D., De Bosscher, K., & D’hooghe, M. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00226 · Cited by 58 · see citing works
Anti-cancer effects of naturally derived compounds targeting histone deacetylase 6-related pathways
Lernoux, M., Schnekenburger, M., Dicato, M. A., & Diederich, M. F. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.11.004 · Cited by 49 · see citing works
Osko, J. D., Porter, N. J., Poli, A. N. R., Xiao, Y., Rokka, J., Jung, M., Hooker, J. M., Salvino, J. M., & Christianson, D. W. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01540 · Cited by 56 · see citing works
Self-citationSixto‐López, Y., Bello, M., & Correa‐Basurto, J. (2018) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2018.1441072 · Cited by 49 · see citing works
“In addition to the catalytic site, there are two other metalbinding sites in HDAC crystal structures (particularly in class I, IIa and IIb (Hai & Christianson, 2016; Micelli & Rastelli, 2015; Vannini et al., 2004)), the so-called site 1 and site 2, which include structural features that accommodate…”
BackgroundNovel spiroindoline HDAC inhibitors: Synthesis, molecular modelling and biological studies
Brindisi, M., Senger, J., Cavella, C., Grillo, A., Chemi, G., Gemma, S., Cucinella, D. M., Lamponi, S., Sarno, F., Iside, C., et al. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.07.069 · Cited by 52 · see citing works
“In particular, keeping in mind the notion that HDAC6, differently from other isoforms, can accommodate bulky rigid cap groups [37, 38], we aimed at building a c ap group able to nicely accommodate in the HDAC binding site while also targeting a specific l pophilic pocket identified in HDAC6 and shaped by three residue…”
BackgroundResultKönig, B., Watson, P. R., Reßing, N., Cragin, A. D., Schäker‐Hübner, L., Christianson, D. W., & Hansen, F. K. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01345 · Cited by 56 · see citing works
Self-citationUstinova, K., Nováková, Z., Saito, M., Meleshin, M., Mikesova, J., Kutil, Z., Baranová, P., Havlínová, B., Schutkowski, M., Matthias, P., et al. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.011243 · Cited by 48 · see citing works
“substrates tested so far, including tubulin and microtubules (13, 14, 26, 37).”
BackgroundStenzel, K., Hamacher, A., Hansen, F. K., Gertzen, C. G. W., Senger, J., Marquardt, V., Marek, L., Marek, M., Romier, C., Remke, M., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01538 · Cited by 51 · see citing works
A novel class of anthraquinone-based HDAC6 inhibitors
Song, Y., Lim, J., & Seo, Y. H. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.12.056 · Cited by 44 · see citing works
Menden, H. L., Xia, S., Mabry, S. M., Noel‐MacDonnell, J., Rajasingh, J., Ye, S. Q., & Sampath, V. (2019) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00247.2018 · Cited by 46 · see citing works
“HDAC6 point mutations in the second catalytic domain (D649N, H651V, and H652V) were introduced by two-step PCR strategy and cloned into pIRES-EGFP-Puro (19).”
BackgroundMethodBifunctional HDAC Therapeutics: One Drug to Rule Them All?
Smalley, J. P., Cowley, S. M., & Hodgkinson, J. T. (2020) · Molecules · doi:10.3390/molecules25194394 · Cited by 47 · see citing works
Development of the first non-hydroxamate selective HDAC6 degraders
Keuler, T., König, B., Bückreiß, N., Kraft, F. B., König, P., Schäker‐Hübner, L., Steinebach, C., Bendas, G., Gütschow, M., & Hansen, F. K. (2022) · Chemical Communications · doi:10.1039/d2cc03712b · Cited by 55 · see citing works
Krieger, V., Hamacher, A., Cao, F., Stenzel, K., Gertzen, C. G. W., Schäker‐Hübner, L., Kurz, T., Gohlke, H., Dekker, F. J., Kassack, M. U., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01489 · Cited by 59 · see citing works
Reßing, N., Sönnichsen, M., Osko, J. D., Schöler, A., Schliehe‐Diecks, J., Skerhut, A. J., Borkhardt, A., Hauer, J., Kassack, M. U., Christianson, D. W., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01888 · Cited by 54 · see citing works
Self-citationSaraswati, A. P., Relitti, N., Brindisi, M., Osko, J. D., Chemi, G., Federico, S., Grillo, A., Brogi, S., McCabe, N., Turkington, R. C., et al. (2020) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.0c00395 · Cited by 51 · see citing works
Self-citationSimoben, C., Robaa, D., Chakrabarti, A., Schmidtkunz, K., Marek, M., Lancelot, J., Kannan, S., Melesina, J., Shaik, T., Pierce, R., et al. (2018) · Molecules · doi:10.3390/molecules23030566 · Cited by 44 · see citing works
“Nevertheless, several structures also show hydroxamate derivatives that only coordinate the zinc ion in a monodentate fashion, as clearly seen in some of the newly released crystal structures of zebrafish HDAC6 [28,29].”
BackgroundAlong the Central Dogma—Controlling Gene Expression with Small Molecules
Schneider‐Poetsch, T., & Yoshida, M. (2018) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060614-033923 · Cited by 43 · see citing works
Leonhardt, M., Sellmer, A., Krämer, O. H., Dove, S., Elz, S., Kraus, B., Beyer, M., & Mahboobi, S. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.04.046 · Cited by 44 · see citing works
Tavares, M. T., Kozikowski, A. P., & Shen, S. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112887 · Cited by 52 · see citing works
“8D, PDB code 5EF8) [88], the carbonyl group (C═O) accepts a hydrogen bond from Y745.”
BackgroundRelitti, N., Saraswati, A. P., Chemi, G., Brindisi, M., Brogi, S., Herp, D., Schmidtkunz, K., Saccoccia, F., Ruberti, G., Ulivieri, C., et al. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112998 · Cited by 48 · see citing works
Dong, J., Zheng, N., Wang, X., Tang, C. C., Yan, P., Zhou, H., & Huang, J. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.03.026 · Cited by 43 · see citing works
Rodrigues, D. A., Guerra, F. S., Sagrillo, F. S., Pinheiro, P. D. S. M., Alves, M. A., Thota, S., Chaves, L. D. S., Sant’Anna, C. M. R., Fernandes, P. D., & Fraga, C. A. M. (2020) · ChemMedChem · doi:10.1002/cmdc.201900716 · Cited by 47 · see citing works
Liu, Q., Zhang, B., Wang, Y., Wang, X., & Gou, S. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.114058 · Cited by 49 · see citing works
Chu-Farseeva, Y.-Y., Mustafa, N. B., Poulsen, A., Tan, E. C., Yen, J. J. Y., Chng, W. J., & Dymock, B. W. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.09.024 · Cited by 44 · see citing works
Zn2+-Dependent Histone Deacetylases in Plants: Structure and Evolution
Yruela, I., Moreno–Yruela, C., & Olsen, C. A. (2021) · Trends in Plant Science · doi:10.1016/j.tplants.2020.12.011 · Cited by 41 · see citing works
“As expected, the Zn2+ cofactor is bound to Asp313, His315, and Asp404, by analogy to HDAC6_CD2 (PDB 5EFN) [65], in which the predicted catalytic Tyr side chain is pointed towards it.”
BackgroundInfluentialShinsky, S. A., & Christianson, D. W. (2018) · Biochemistry · doi:10.1021/acs.biochem.8b00079 · Cited by 41 · see citing works
Self-citationRabal, O., Sánchez-Arias, J. A., Cuadrado‐Tejedor, M., de Miguel, I., Pérez-González, M., García, C., Ugarte, A., de Mendoza, A. E., Sáez, E., Espelosin, M., et al. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00303 · Cited by 46 · see citing works
Curriculum vitae of HDAC6 in solid tumors
Zheng, Y., Kang, H., Wang, B., Zhu, Y.-Z., Mamun, M., Zhao, L., Nie, H., Liu, Y., Zhao, L., Zhang, X., et al. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.123219 · Cited by 43 · see citing works
Cellupica, E., Caprini, G., Cordella, P., Cukier, C. D., Fossati, G., Marchini, M., Rocchio, I., Sandrone, G., Vanoni, M. A., Vergani, B., et al. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102800 · Cited by 46 · see citing works
“60 Å resolution; Protein Data Bank [PDB] code: 8A8Z) with the ligand-free protein (PDB code: 5EEM (13)) shows a root mean square deviation value of 0.”
BackgroundMethodInfluentialSinatra, L., Vogelmann, A., Friedrich, F., Tararina, M. A., Neuwirt, E., Colcerasa, A., König, P., Toy, L., Yesiloglu, T. Z., Hilscher, S., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01385 · Cited by 45 · see citing works
“Another coupling cycle with N -Fmoc protected para -aminobenzoic acid provided the respective HDAC inhibitor precursors 49 and 51 (Scheme 3A).”
InfluentialSelf-citationNegmeldin, A. T., Padige, G., Bieliauskas, A. V., & Pflum, M. K. H. (2017) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6b00124 · Cited by 41 · see citing works
Krieger, V., Hamacher, A., Gertzen, C. G. W., Senger, J., Zwinderman, M. R. H., Marek, M., Romier, C., Dekker, F. J., Kurz, T., Jung, M., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00197 · Cited by 45 · see citing works
- Authors
- Hai, Y., & Christianson, D. W.
- Affiliations
- University of Pennsylvania (US)
- Harvard University (US)
- Corresponding author
- Christianson, David W
- Venue
- Nature Chemical Biology
- Published
- 2016-07-25
- Volume
- 12
- Issue
- 9
- Pages
- 741-747
- ISSN
- 1552-4450 (ISSN-L)
- 1552-4469
- PMC
- PMC4990478
- OpenAlex
- W2499955277
- Cited by
- 521
- References
- 61
- Citations by year
- 2026: 56 · 2025: 76 · 2024: 50 · 2023: 55 · 2022: 47 · 2021: 57 · 2020: 54 · 2019: 46 · 2018: 42 · 2017: 29 · 2016: 9
- FWCI
- 23.03
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Chemical Biology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of General Medical Sciences (R01GM049758)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Physical Sciences › Materials Science › Materials Chemistry › Enzyme Structure and Function
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Enzyme function and inhibition
- Keywords
- HDAC6, crystal structure, substrate specificity, catalytic mechanism, belinostat, panobinostat, HC-toxin, zinc coordination, small molecule inhibitors, cancer drug targets
- MeSH terms
- Animals, Histone Deacetylases, Humans, Models, Molecular, Structure-Activity Relationship, Substrate Specificity, Zebrafish, Molecular Structure, Biocatalysis, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Claims read under definition version 3 (extract-v3) on 2026-09-28.
Classified by jev-1.13-20260917 (gold-guideline-v0.2) on 2026-09-28.
Cited sources are checked by gpt-6-sol.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review